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Neurofibromatosis type 2, an autosomal dominant genetic disorder, causes predisposed 
individuals to develop various benign central and peripheral nervous system tumors.  The 
characteristic tumors of this disease are schwannomas, which are tumors of the Schwann 
cells, typically on the vestibular nerve.  These and the other associated tumors slowly 
compress nervous system structures causing deafness and loss of balance, resulting in an 
average life-span of less than 40 years.  The product of the Nf2 gene is the protein named 
merlin or schwannomin.  In individuals diagnosed with NF2, merlin is either absent or 
mutated to the point of inactivation.  As such, merlin functions as a negative growth 
regulator in that it suppresses tumor growth.  Being that NF2 is predominately a disease 
of the Schwann cells, merlin’s functional role within the signal transduction pathways of 
Schwann cell growth and differentiation are being investigated.  This thesis explores the 
molecular relationships between merlin and its various interactors within Schwann cells, 
and illuminates one step in elucidating merlin’s functional mechanism of action.  Merlin 
has been shown to associate with paxillin in a density-dependant manner and to bind 
directly to paxillin through two specific paxillin binding domains.  Individual paxillin LD 
domain fusion proteins were produced, as well as recombinant merlin lacking the paxillin 
binding domains.  Direct binding assays were performed in order to determine which 
specific paxillin domains merlin might interact with directly.  The results indicate that, in 
vitro, merlin binds, through its PBD1 domain, to the paxillin LD3 motif.  Supporting this
 ii
data, the results also demonstrate that when the merlin PBD1 domain is deleted, merlin 
binding to paxillin LD3 is abrogated.  The direct binding shown here between paxillin 
and merlin, coupled with research demonstrating that merlin is present in β1 integrin 
immuno-precipitations, leads to the question of whether merlin binds directly to β1 
integrin or associates with β1 integrin through paxillin.  Using direct binding assays, this 
research shows that the merlin C-terminus binds directly to the cytoplasmic domain of β1 
integrin, in vitro.  Lastly, since merlin is an ERM family protein and has been shown to 
dimerize with ezrin (another ERM family member), and because merlin has been shown 
to bind directly to paxillin, the question asked is whether paxillin can interact directly 
with ezrin.  The results indicate that paxillin can bind directly to the N-terminus of ezrin, 
in vitro.  The findings presented here, when examined together, provide a framework for 
the proposal of a model in which paxillin LD3 mediates the localization of merlin to the 
plasma membrane, where it associates with the β1 integrin cytoplasmic domain and ezrin.  
These results and the proposed model offer additional insight into the mechanism of 






First and foremost, I would like to thank my husband, Mike Geden, for his loving 
support throughout my extensive “career change”.  Mike, I promise I won’t go back to 
school for a PhD… at least until I’m 55!  Thanks also go to my children, Daniel and 
Alex, for putting up with a mother who kept saying, “I can’t, I have to study”, or, “Not 
now, I have to go to the lab.”  I love you guys and I apologize for the missed time.  
Amazingly enough, both boys want to be scientists when they grow up.  Many thanks go 
to my lab mates Marga Bott and Jared Iacovelli.  In addition to answering my chemistry 
questions, Marga provided friendship and emotional support.  And, although Jared and I 
sat back to back, I often used him as a sounding board for experiment ideas and as a 
double-checker on my calculations when I was just too tired to think straight.  I would 
also like to thank Dr. Lucia Cilenti for all her guidance and for her considerable patience 
in answering my too-numerous-to-count questions, and Kathleen Nemec also deserves a 
round of thanks for her unflappable emotional support throughout the years.  Special 
thanks go out to JoAnn Licht and Judy Gerrard for their friendship and spiritual support; I 
couldn’t have finished it without you.  Finally, I would like to acknowledge my advisor, 
Dr. Cristina Fernandez-Valle.  Dr. Valle has an amazingly sharp mind, and I can only 
hope to acquire the memory for scientific detail that she posseses.  Thank you, Dr. Valle, 
for the privilege of working in your lab. 
 
 iv
TABLE OF CONTENTS 
 
LIST OF FIGURES .......................................................................................................... vii 
LIST OF TABLES............................................................................................................. ix 
INTRODUCTION .............................................................................................................. 1 
LITERATURE REVIEW ................................................................................................... 2 
Schwann Cell Biology: Differentiation ..................................................................... 2 
Focal Adhesions and Integrins................................................................................... 4 
Neurofibromatosis Type 2 ....................................................................................... 10 
Merlin....................................................................................................................... 12 
Ezrin: An ERM Family Member ............................................................................. 17 
Paxillin ..................................................................................................................... 21 
Specific Aims........................................................................................................... 25 
MATERIALS AND METHODS...................................................................................... 28 
Materials .................................................................................................................. 28 
Methods.................................................................................................................... 30 
Cell Culture ......................................................................................................... 30 
Schwann Cell Protein Extraction ........................................................................ 30 
Electro-competent Bacteria Production............................................................... 31 
Generation of His-Merlin Constructs .................................................................. 32 
Binding Assays ........................................................................................................ 34
 v
Affinity Pull-down Assay (Indirect Binding)...................................................... 34 
Direct Binding Assays......................................................................................... 36 
Western Blot Analysis ............................................................................................. 37 
RESULTS ......................................................................................................................... 38 
Recombinant Protein Expression and Purification .................................................. 38 
GST-Paxillin Fusion Proteins.............................................................................. 38 
His-Paxillin Fusion Proteins................................................................................ 40 
His-Merlin Fusion Proteins ................................................................................. 44 
GST-Ezrin Fusion Proteins ................................................................................. 45 
GST-β1 Integrin Cytoplasmic Domain (CD) Fusion Proteins ............................ 48 
Binding Assays ........................................................................................................ 53 
Merlin–Paxillin Interactions................................................................................ 53 
Affinity Pull-down Assay (Indirect Binding)................................................ 53 
Direct Binding Assays................................................................................... 55 
Merlin-β1 Integrin Interactions ........................................................................... 61 
Paxillin-Ezrin Interactions................................................................................... 65 
DISCUSSION................................................................................................................... 68 
Merlin-Paxillin Interactions ..................................................................................... 69 
Merlin-β1 Integrin Interactions................................................................................ 70 
Paxillin-Ezrin Interactions ....................................................................................... 74 
Proposed Model of Merlin/Paxillin/β1 Integrin/Ezrin Interactions......................... 75 
REFERENCES ................................................................................................................. 77
 vi
LIST OF FIGURES 
Figure 1.  Structure of Typical Integrin. ............................................................................. 6 
Figure 2.  Depiction of Integrin Activation. ....................................................................... 7 
Figure 3.  β1 Integrin Cytoplasmic Domain. ...................................................................... 9 
Figure 4.  Merlin Structure with Corresponding Exons.................................................... 13 
Figure 5.  Closed and Open Conformations of Merlin. .................................................... 15 
Figure 6.  Structure of Ezrin. ............................................................................................ 19 
Figure 7.  Structure of Paxillin.......................................................................................... 23 
Figure 8.  Confirmation of Positive His-Merlin Clones. .................................................. 35 
Figure 9.  Expression and Purification of GST-Paxillin Fusion Proteins. ........................ 41 
Figure 10.  Expression and Purification of the His-Paxillin Fusion Protein..................... 43 
Figure 11.  Expression and Purification of the His-Merlin Fusion Proteins..................... 46 
Figure 12.  Expression and Purification of GST-Ezrin Fusion Proteins........................... 49 
Figure 13.  Expression and Purification of the GST-β1cd Fusion Proteins...................... 52 
Figure 14.  GST-Paxillin Full-Length and N-Terminus Bind to Merlin From Confluent 
Schwann Cell Lysate................................................................................................. 54 
Figure 15.  GST-Paxillin-LD3 Binds Directly to His-Merlin N-Terminus. ..................... 57 
Figure 16.  GST-Paxillin-LDs 2 and 3, Predominantly, Bind Directly to His-Merlin C-
Terminus. .................................................................................................................. 58
 vii
Figure 17.  GST-Paxillin LD3 Binds Directly to His-Merlin N Term, but Not to His-
Merlin N Term Lacking the PBD1 Domain. ............................................................ 60 
Figure 18.  GST-β1 Integrin Cytoplasmic Domain Binds Directly to His-Merlin 1, His-
Merlin 2, and His-Paxillin......................................................................................... 62 
Figure 19.  The GST-β1 Cytoplasmic Domain Binds Directly to the C-Terminus .......... 64 
Figure 20.  His-Paxillin-FL Binds to the Ezrin-N-Terminus Under High Salt Buffer 
Conditions. ................................................................................................................ 67 
Figure 21.  The 1st Direct Binding Partner for the Paxillin LD3 Domain Has Been 
Identified as the Merlin PBD1 Domain. ................................................................... 71 
Figure 22.  Merlin/Paxillin/β1 Integrin Binding Model. .................................................. 73 
Figure 23.  Model of Merlin/Paxillin/β1 Integrin/Ezrin Interactions in Proliferating and 
Quiescent Schwann Cells.......................................................................................... 76
 viii
LIST OF TABLES 
Table 1.  Primary Antibodies. ........................................................................................... 28 
Table 2.  Secondary Antibodies. ....................................................................................... 28 





The long-term goal of the research conducted for this thesis is to understand the 
tumor growth-suppression function of the Nf2 gene product, the protein merlin, in the 
etiology of the disease Neurofibromatosis Type 2.  In general, this thesis research 
investigates the interactions between merlin and various proteins within the context of 
merlin’s role in the signal transduction pathways of Schwann cells, the cell type 
predominantly affected in Neurofibromatosis Type 2. 
An overview of Schwann cell biology, focal adhesions, and integrins is presented 
first in the Literature Review, followed by a summary of the clinical, genetic, and 
molecular aspects of Neurofibromatosis Type 2.  Subsequent sections provide detailed 
background information concerning each protein relevant to this thesis research.  Lastly, 
previous research and results obtained from this lab are discussed, leading to a statement 
of the specific aims for this thesis research. 
Following the Literature Review, the Materials and Methods section lists all 
pertinent materials utilized for this research, as well as the methods employed to conduct 
these experiments.  The individual results obtained for each question listed in the Specific 
Aims are presented in the Results section.  To finish, the Discussion section presents an 
examination of the results, including conclusions and a proposed model detailing the 




Schwann Cell Biology: Differentiation 
 
The majority of cells present within any nervous system are the non-neural cells 
known as glia.  Within vertebrate nervous systems, four major glial cell types are 
recognized; these are astrocytes, microglial cells, oligodendrocytes, and Schwann cells 
(SCs).  The first three cell types are found only in the central nervous system (brain and 
spinal cord), while SCs are found only in the peripheral nervous system. 
Development of the vertebrate peripheral nervous system is regulated by a series 
of complex interactions between the outgrowing neuronal axons and the developing SCs 
(Maurel and Salzer, 2000).  SCs begin their existence as a transient group of cells, known 
as neural crest cells, which migrate out from the neural tube at the initiation of embryonic 
development (Haack and Hynes, 2001).  During embryonic growth, a sub-population of 
the neural crest cells begins migrating along pre-existing axon tracts on the developing 
peripheral nerve trunks (Bunge and Fernandez-Valle, 1995).  Throughout embryogenesis, 
the neural crest cells consecutively differentiate into two intermediate cell types; first into 
SC precursor cells, then into immature SCs (Jessen and Mirsky, 2002).  At this point in 
development, the survival, proliferation, and differentiation of these intermediate cell 
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types is extremely dependent upon many signaling factors, such as contact-dependent 
mitogens derived from the axons (Garratt et al., 2000; Zanazzi et al., 2001).  In one study,
mice with specific disruptions of the neuregulin-1 gene exhibited a major shortage of 
precursor SCs (Meyer and Birchmeier, 1995).  A severe deficiency in this cell type 
affects the developing neurons, as adequate precursor SCs are required for neuronal 
survival (Scherer, 2002). 
As the SC precursors differentiate into immature SCs, they begin to surround 
large bundles of axons.  In a process termed radial sorting, the axons are penetrated by 
thin SC cytoplasmic processes that segregate the axons into smaller and smaller bundles 
(Feltri et al., 2002).  Concurrent with the sorting, the evolving SCs deposit a specialized 
form of extracellular matrix known as basal lamina (Scherer, 2002).  As the sorting 
process continues, bundles of smaller diameter axons remain enveloped by cords of 
immature SCs (Scherer, 2002).  These are the cells that, with maturation, become 
ensheathing SCs. 
As the immature SCs actively compete for axonal domain, segments of the larger 
diameter axons become individually surrounded by a single immature SC (Bunge and 
Fernandez-Valle, 1995).  Competition for axonally-derived trophic factors guarantees 
that the number of immature SCs produced is sufficient for the number of axons present 
and for their length.  When the appropriate quantity of immature SCs has been generated, 
around the time of birth, the axons, together with their layer of basal lamina, induce SC 
differentiation (Zanazzi et al., 2001).  The immature SCs differentiate into one of two 
mature SC types; these are known as myelinating, which arise first, and non-myelinating, 
also called ensheathing, which develop later (Mirsky et al., 2002). 
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Myelinating SCs form the myelin sheath, which is an important feature of motor 
and sensory neurons within the peripheral nervous system, as it acts as an electrical 
insulator.  This allows for the extremely rapid conduction of nerve impulses due to a 
lowering of the axonal membrane capacitance.  Proper myelination occurs only when 
SCs have deposited an organized basal lamina, which is a specialized type of 
extracellular matrix (ECM) (Schuppan et al., 1994).  Studies show that interference with 
synthesis of SC basal lamina disrupts myelination (Fernandez-Valle et al., 1994; Feltri et 
al., 2002).  Formation of a myelin segment commences when a mature SC advances one 
lip of its encircling membrane under the opposing lip of the cell.  The underlying edge of 
the membrane continues to force itself under the overlying SC cytoplasm and around the 




Focal Adhesions and Integrins 
 
Focal adhesions (FAs) are specialized areas of tight attachment between a cell and 
its underlying ECM where integrin receptors link the actin cytoskeleton to the ECM 
(Sastry and Burridge, 2000).  As such, FAs provide a structural link between the actin 
cytoskeleton and the ECM for the purpose of adhesion and motility (Burridge and 
Chrzanowska-Wodnicka, 1996).  In addition, FAs are sites of signal propagation and 
transduction that have an influence on basic cellular functions such as growth control and 
apoptosis (Woodrow et al., 2003).  A FA complex consists of the ECM components such 
 4
as collagens, noncollagenous glycoproteins (laminin, fibronectin), and proteoglycans, the 
cytoplasmic components such as actin, FAK (focal adhesion kinase), and paxillin, and 
lastly, the transmembrane components (Schuppan et al., 1994). 
The major transmembrane components of FAs are integrins, which are a large 
family of heterodimers composed of α and β subunits (Schuppan et al., 1994; Previtail et 
al., 2001).  Figure 1 illustrates the structure of integrin heterodimers.  There are at least 
18 variants of the integrin α subunit and 8 variants of the β subunit, therefore a variety of 
heterodimers can be formed which promote integrin diversity (Lee and Juliano, 2002).  
Integrins are composed of a large extracellular head domain responsible for ligand 
binding, a single-pass transmembrane segment, and, in all cases except one (the β4 
chain), a short cytoplasmic tail of less than 50 amino acids (Liu et al., 2000; Liddington, 
2002; Hynes, 2002).  Integrins play a major role in cell adhesion and migration, and they 
exert control over cell differentiation, proliferation, and apoptosis (Liu et al., 2000). 
Integrins mediate the transduction of signals through the cell membrane in both 
directions.  “Outside-in” signaling occurs when extracellular ligands bind to the 
heterodimeric head triggering conformational changes which lead to a separation of the 
cytoplasmic tails (Hynes, 2003).  This, in turn, allows the tails to bind intracellular 
proteins which then propagate the transmission of signals into the cell resulting in cellular 
differentiation, gene expression, and cytoskeletal reorganization (Liu et al., 2000; 
Liddington, 2002).  “Inside-out” signaling, on the other hand, occurs when cytosolic 
proteins bind to one of the integrin cytoplasmic tails.  This binding triggers a 
conformational change in the integrin extracellular head, resulting in a high-affinity 












Figure 1.  Structure of Typical Integrin. 
Integrins are composed of two non-covalently associated α and β subunits.  The 
extracellular domain contains the ligand binding region.  The cytoplasmic domains 
of both subunits are relatively small and contain regions capable of binding various 










clustered inactive active 
 
 
Figure 2.  Depiction of Integrin Activation. 
(Left) In the inactive state, the αβ heterodimer is bent over and does not bind 
to its extracellular ligands.  (Middle) When activated, the αβ heterodimer is stablilized 
either by its extracellular ligand or by intracellular cytoskeleton protein binding, such as 
talin.  (Right) Clustering of integrins leads to the formation of a signaling complex.  
Adapted from Hynes, 2003. 
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of the earliest proteins to be recruited to FAs in the leading edge of ruffling cells, and it 
only becomes tyrosine phosphorylated after integrin ligand binding (Lamorte et al., 
2003).  Tyrosine phosphorylation of paxillin has been shown to be essential for FA 
formation and the reorganization of the actin cytoskeleton (Lamorte et al., 2003). 
Specifically, β1 integrin plays an important role in SCs.  In immature and 
promyelinating SCs, the α6β1 integrin is expressed, while myelinating SCs mainly 
express α6β4 integrin (Previtali et al., 2001).  Immature SCs require β1 integrin to 
properly segregate axons during development, and promyelinating SCs require β1 
integrin to adhere to their basal laminae in order to initiate the formation of the myelin 
sheath (Scherer, 2002). 
More to the point, β integrin cytoplasmic tails, with their NPXY consensus motif, 
have been shown to be essential for the correct subcellular localization of integrins and 
for the regulation of the affinity of integrins for their ligands (Liu et al., 2000).  
Additionally, β1 integrin cytoplasmic tails have been shown to be necessary for the 
activation of signaling pathways (Liu et al., 2000).  As seen in Figure 3, the β1 integrin 
cytoplasmic domain, in particular, exhibits a wide variety of binding partners which 
range from actin-binding proteins such as talin, to signaling proteins such as the kinases 
ILK and FAK, and lastly, to miscellaneous proteins such as the adaptor protein paxillin 
(Liu et al., 2000).  The β1 integrin cytoplasmic domain has also been shown to interact 
with merlin in isolated and differentiating SCs, and during differentiation paxillin and 
FAK assemble into a β1 integrin multi-molecular complex induced by basal lamina 
















Figure 3.  β1 Integrin Cytoplasmic Domain. 
Locations of various binding partners are displayed.  Note the NPXY motifs, which are 
important for integrin-mediated FAK association and activation.  Adapted from 







Neurofibromatosis Type 2 
 
Neurofibromatosis type 2 (NF2), formerly named central or bilateral acoustic 
neurofibromatosis (Brockes, 1986), is an autosomal dominant genetic disorder caused by 
the bi-allelic inactivation of the Nf2 gene.  Any children of an affected individual have a 
50 percent risk of tumor formation (Martuza and Eldridge, 1988).  The hallmark criterion 
for diagnosis of NF2 is the development of bilateral SC tumors, or schwannomas, on the 
vestibular branch of the eighth cranial nerves, those responsible for hearing (Rouleau et 
al., 1990).  Accordingly, the first symptom of NF2 is usually hearing loss (Martuza and 
Eldridge, 1988).  In addition to schwannomas, individuals with NF2 are predisposed to 
the development of various central nervous system (CNS) tumors such as meningiomas, 
spinal neurofibromas, ependymomas, and gliomas (Gutmann et al., 1997).  The majority 
of these tumors are benign; with less than 1% ever undergoing malignant transformation 
(Wagner, 2003).  Growth of these various NF2-associated tumors can cause a number of 
symptoms such as vertigo and paralysis, as well as extreme pain caused by the 
compression of nervous system structures over time (Rouleau et al., 1990; Martuza and 
Eldridge, 1988).  The NF2 disorder affects between 1 in 33,000 to 40,000 live births 
(Ruggieri and Huson, 1999; Pykett et al., 1994), and the average life-span of affected 
individuals is typically less than 40 years (Gusella et al., 1999). 
The gene suspected of involvement in the NF2 disorder was localized to 
chromosome 22 by the use of genetic linkage analysis and deletion mapping of both 
hereditary and sporadic schwannomas (acoustic neuromas) and meningiomas from NF2 
patients (Seizinger et al., 1986; Seizinger et al., 1987a; Seizinger et al., 1987b; Dumanski 
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et al., 1987).  These same studies suggested that the NF2 locus encoded a tumor 
suppressor gene.  A mutation in a tumor suppressor gene inactivates that gene’s protein 
product, which normally aids in the inhibition of cell proliferation.  Unregulated cell 
growth consequentially occurs, resulting in tumor formation.  Subsequent cytogenetic 
research narrowed the location of the purported NF2 gene to within the q12 region of 
chromosome 22 (Rouleau et al., 1987; Wertelecki et al., 1988; Rouleau et al., 1990; 
Narod et al., 1992; Wolff et al., 1992; Frazer et al., 1992).  This same research 
additionally supported the theory of a tumor suppressor gene associated with the etiology 
of NF2.  Studies were able to show that NF2 patients, with an inherited mutant allele of 
the purported NF2 gene, were predisposed to tumor formation, occurring as a direct result 
of a somatic mutation in the remaining wild type allele (Hovens and Kaye, 2001). 
In 1993, two independent research groups definitively identified the NF2 gene 
through the use of positional cloning and chromosome walking.  Both groups declared 
that the predicted protein product of this gene showed significant sequence homology to 
the ERM (ezrin-radixin-moesin) proteins (Bretscher et al., 2000).  One group named this 
novel protein merlin (moesin, ezrin, and radixin-like protein) due to its similarity to the 
ERM proteins, while the other group named the protein product schwannomin, from 
schwannoma – the predominant tumor type seen in NF2 patients (Trofatter et al., 1993; 




Merlin is composed of 17 exons that, with alternative splicing, generate two major 
isoforms.  As seen in Figure 4, isoform I consists of 595 amino acids and is encoded by 
exons 1 through 15 and 17.  Isoform II, a 590 amino acid protein, is encoded by exons 1 
through 16 and is identical to isoform I over the first 579 residues (Bianchi et al., 1994).  
The presence of exon 16 in isoform II results in a modified carboxy terminus (C-term) 
due to the addition of 11 amino acids followed by a stop codon that prevents the 
translation of exon 17 (Gusella et al., 1996).  Research has shown that mutations linked to 
the NF2 disorder occur throughout the entire NF2 gene, with the exception of exons 16 
and 17 (Sainio et al., 2000).  The majority of NF2 mutations are hypothesized to result in 
truncated merlin proteins (den Bakker et al., 2000), with these types of mutations being 
associated with the more severe forms of NF2 (Sainio et al., 2000).  Milder forms of NF2 
are associated with missense mutations, and several exon 2 missense mutations and in-
frame deletions, which produce measurable but dysfunctional merlin proteins, have been 
identified (Fernandez-Valle et al., 2002; Gutmann et al., 1998). 
Similar to the ERM proteins after which it was named, merlin is composed of 
three structural domains as depicted in Figure 4 (Shimizu et al., 2002).  The amino (N)-
terminal FERM [protein 4.1 (four point one), ERM] domain consists of residues 1 
through 310, while residues 311 to 478 comprise a large α−helical region (Chishti et al., 
1998).  The unique C-terminal domain of isoform I, composed of residues 479 through 
595, lacks the actin-binding region conserved among other ERM proteins (Xiao et al., 



















Figure 4.  Merlin Structure with Corresponding Exons. 
Merlin is composed of three major stuctural domains: the N-terminal FERM domain, the 
coiled-coil (CCR) or α-helical region, and the C-terminal tail.  Note the locations of 




of three well-defined sub-domains, A, B, and C, which exhibit a three- dimensional 
cloverleaf structure (Sun et al., 2002).  Present in sub-domain B is a run of 7 amino acids, 
residues 177 to 183, referred to as the Blue box (LaJeunesse et al., 1998).  Although the 
Blue box region is identical in human merlin and the Drosophila homologue, it is not 
conserved among the other ERMs (LaJeunesse et al., 1998). 
Research demonstrates that, similar to the ERM proteins, merlin isoform I is able 
to form two distinct intramolecular associations in vitro (Sherman et al., 1997; Gutmann 
et al., 1998).  One such association transpires between the N-term and the C-term, 
specifically between residues 302-308 (within sub-domain C) and residues 580-595 (exon 
17) (Gutmann et al., 1999).  The other intramolecular association occurs between the 
extreme ends of the N-term itself, between sub-domains A and C, and is required for the 
stabilization of the N-term/C-term interaction (Gutmann et al., 1999).  Because of its 
ability to associate intramolecularly, merlin isoform I can exist in two conformational 
states: closed and open (Gutmann et al., 1999).  As depicted in Figure 5, the closed 
conformation is considered the active form and occurs through the N-term/C-term 
intramolecular association, while the open conformation is the inactive form (Gutmann, 
2001).  Studies show that the loss of just the final two C-terminal amino acids of merlin is 
enough to impair its self-association (Gutmann et al., 1999), thereby rendering the protein 
open and inactive. 
Research has shown that merlin isoform I, which can self-associate, inhibits the 
growth of fibroblasts and RT4 rat schwannoma cells in vitro and in vivo (Lutchman and 
Rouleau, 1996; Sherman et al., 1997).  Wild-type merlin typically localizes to the plasma 












inactive / growth permissiveactive / tumor suppressor 
 
 
Figure 5.  Closed and Open Conformations of Merlin. 
Merlin can adopt two conformations: closed and open.  The closed conformation is the 
active tumor suppressor form, and the open conformation is the inactive or growth 
permissive form.  Adapted from Martin et al., 2003. 
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al., 1996), and research has demonstrated that merlin can interact directly, in vitro, with 
actin (Deguen et al., 1998) through a unique N-terminal domain (residues 178-367) (Xu 
and Gutmann, 1998).  LaJeunesse et al. have demonstrated that residues 177 to 183, the 
Blue box domain, of merlin are important for subcellular localization (LaJeunesse et al., 
1998).  Additionally, studies have shown that self-association of the merlin N-term is 
required for actin association and for the proper localization of merlin at the plasma 
membrane (Brault et al., 2001), and the N-term of merlin has been shown to localize, in 
vitro, to filopodia, cytoskeleton features, and the plasma membrane (Fernandez-Valle et 
al., 2002).  Together, these data support the hypothesis that merlin’s ability to alter its 
conformational state by intramolecular self-association, and by extension its localization, 
are critical to its function as a negative growth regulator (Sherman et al., 1997; Gutmann 
et al., 1998). 
Past studies have suggested that merlin isoform II is unable to self-associate 
(Sherman et al., 1997; Gonzalez-Agosti et al., 1999) thus leading to the conclusion that 
merlin isoform II lacks tumor suppressor activity (Gutmann et al., 1998).  More recently, 
however, research has demonstrated that isoform II does undergo intramolecular self-
association, although in a uniquely different manner than that of isoform I, thereby 
suggesting that, while merlin isoform II doesn’t function as a tumor suppressor, it does 
have unique functional properties (Scoles et al., 2002). 
Various studies show that merlin’s conformation alternates between the open 
(inactive) and closed (active) states in response to numerous factors, such as 
phosphorylation, and that these factors also contribute to its tumor suppressor activity 
(Sun et al., 2002).  Western blot analysis of U2OS and NIH3T3 cells has demonstrated 
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that merlin isoform I is differentially phosphorylated as detected by the presence of a 
doublet (6% gel) at approximately 70 kDa (Shaw et al., 1998b).  Specifically, the slower 
migrating form represents the phosphorylated merlin, while the faster migrating form 
represents the unphosphorylated merlin (Shaw et al., 1998b).  Research suggests that 
unphosphorylated merlin most likely represents the active, and therefore closed, form of 
merlin (Shaw et al., 1998b).  In support of this conclusion, recent studies show that 
merlin is phosphorylated on serine 518 (S518) by activated Rac/cdc42, and that this 
phosphorylation disrupts the merlin N-term/C-term self-association required for the 
active, i.e. growth suppressive, closed conformation (Shaw et al., 2001).  Additional 
research, which utilized constitutively active forms of Rac/cdc42 kinase effectors and 
immunodepletion assays, reveals that merlin phosphorylation of S518 is induced 
specifically by PAK2, via activated Rac/cdc42, in NIH3T3 cells (Kissil et al., 2002).  In 
support of this data, a recent study demonstrates that PAK2 directly phosphorylates wild-
type merlin at S518, and additionally shows that this phosphorylation disrupts the merlin 
N-term/C-term self-association, in vitro and in vivo (Rong et al., 2004). 
 
 
Ezrin: An ERM Family Member 
 
The ERM family of proteins, which include ezrin, radixin, and moesin, belong to 
the protein 4.1 superfamily of membrane organizing proteins (Simons et al., 1998).  All 
of this superfamily’s members, of which merlin is one, share significant homology within 
the N-terminal FERM domain (Grönholm et al., 1999).  The ERMs function as vital 
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cross-linkers between the actin cytoskeleton and the plasma membrane (Bretscher et al., 
2000).  As such, their interactions with both membrane proteins and the cortical actin 
cytoskeleton are essential for many basic cellular processes, including adhesion, motility, 
cell morphogenesis, cytokinesis, and transduction of growth signals for survival and 
proliferation (Gautreau et al., 2002; Bretscher et al., 2002). 
Ezrin is a 13 exon protein with an apparent molecular weight of ~82 kDa 
(Bretscher et al., 2000; Tsukita and Yonemura, 1999).  Like merlin, ezrin and its family 
members are composed of three major structural domains consisting of the FERM 
domain, a coiled-coil or α−helical region, followed by the C-terminal domain (Sun et al., 
2002).  The structure of ezrin is illustrated in Figure 6.  Crystallographic analysis of the 
family’s FERM domains reveals that, like merlin, ezrin and the ERMs are composed of 
three structural sub-domains, lobes F1, F2, and F3, which are analogous to merlin’s sub-
domains A, B, and C (Smith et al., 2003).  While there are many similarities between 
merlin and ERM proteins, some key structural differences exist also.  Ezrin and the ERM 
proteins possess an F-actin-binding site within the C-terminus, while merlin does not 
(Gusella et al., 1999).  Additionally, merlin sub-domain B contains a stretch of 7 amino 
acids (residues 177 to 183) referred to as the Blue box, which is identical in human 
merlin and the Drosophila homologue, but which is not conserved among the ERMs 
(LaJeunesse et al., 1998). 
Like merlin, ezrin and its ERM members can undergo intramolecular self-
association in which the N-terminal domain binds to the C-terminal domain with high 





















Figure 6.  Structure of Ezrin. 
Ezrin is composed of three major structural domains: the N-ERMAD or N-terminal 
FERM domain, the coiled-coil (CCR) or α-helical region, and the C-terminal C-ERMAD.  
Note the location of the F-actin binding domain.  Adapted from Sun et al., 2002. 
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undergoing homotypic and heterotypic dimerization, through binding between their 
various N- and C-terminal domains (Bretscher et al., 2000).  The discovery that the N-
terminal domain of any ERM was able to bind to the C-terminal domain of any other 
ERM led these regions to be named N- and C-ERMAD for ERM association domain 
(Gary and Bretscher, 1995).  In ezrin, the N-ERMAD was found to be coincident with the 
FERM domain, and this region encompasses amino acids 1 through 296 (Grönholm et al., 
1999).  The C-ERMAD of ezrin is composed of residues 479 through 585 (Gary and 
Bretscher, 1995). 
Ezrin and the ERMs are negatively regulated by the conformational changes that 
occur as the result of their intramolecular and intermolecular associations (Bretscher et 
al., 2002).  As such, ERM monomers are thought to be maintained in a closed or dormant 
conformation in which the N-ERMAD and C-ERMAD domains are in high affinity 
association with each other (Grönholm et al., 1999; Gautreau et al., 2002).  In this 
inactive form, the C-ERMAD has an elongated tail which covers a large portion of lobes 
F2 and F3 of the FERM domain, thereby masking both the FERM domain binding sites 
and the C-ERMAD F-actin binding site (Pearson et al., 2000).  Additionally, it has been 
suggested that homotypic and heterotypic ERM oligomers also represent inactive forms, 
as their head-to-tail intermolecular associations also mask their respective FERM and C-
ERMAD binding sites (Grönholm et al., 1999). 
As the dormant state of the ERMs is the closed conformation, it follows that the 
open conformation of ezrin and the ERMs requires that the FERM and C-ERMAD 
domains become separated.  Studies show that multiple stimuli can activate the ERMs, 
and in all cases these stimuli result in ERM phosphorylation (Gautreau et al., 2002).  
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Research demonstrates that hyperphosphorylation of a corresponding threonine (T) 
residue within the C-terminal tail of all the ERMs (T567 in erzrin) was shown to 
significantly reduce the affinity of the C-ERMAD for the FERM domain, in vitro (Matsui 
et al., 1998).  Rho kinase, protein kinase Cα (PKCα), and PKCθ are kinases which have 
been shown, both in vitro and in vivo, to phosphorylate the C-terminal ERM threonine 
(Bretscher et al., 2002).  Specifically, ezrin phosphorylation by PKCθ, in the presence of 
lipids, has been shown to unmask the F-actin and EBP50 binding sites (Simons et al., 
1998).  Because the phosphorylation of ezrin occurs in the presence of phospholipids, it 
has been suggested that lipids may also be involved in ERM activation.  In fact, one study 
suggests that the conserved threonine phosphorylation of ERMs may not be required at 
all for activation (Matsui et al., 1998).  To further this hypothesis, Matsui et al. conducted 
additional research, the results of which suggest that PIP2 (phosphatidylinositol-4,5-
bisphosphate) directly activates the ERMs by binding to the FERM domain, and that the 
activated ERM proteins are then phosphorylated at their C-terminal residue for 
stabilization (Matsui et al., 1999).  In support of this theory, research shows that when the 
ERM PIP2 binding site is mutated, ezrin alters it localization from the membrane to the 





Paxillin is a 559-amino acid FA-associated adaptor protein with an apparent 
molecular weight of ~68 kDa (Tumbarello et al., 2002).  It is highly conserved between 
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species, showing at least 90% identity between human and chickens, and it is abundantly 
expressed in a wide variety of tissues (Turner, 2000).  In general, adaptor proteins, 
through their multi-domain structure, perform the essential task of facilitating 
transduction of both adhesion- and growth factor-dependent signals at the plasma 
membrane (Turner, 2000).  Specifically, paxillin is thought to function as a scaffold for 
the recruitment of various cytoskeleton and signaling proteins to FA complexes, and 
there, to integrate these signals for transmission downstream (Schaller, 2001).  The 
paxillin superfamily consists of paxillin, Hic-5, leupaxin, and PaxB, all of which share 
highly conserved domains within their N- and C-termini (Tumbarello et al., 2002).  
DALP, the death-associated LIM-only protein, is another member of the paxillin 
superfamily, but differs from the other members in that it is comprised solely of Lin-11, 
Isl-1, Mec-3 (LIM) domains (Turner, 2000). 
As illustrated in Figure 7, the structure of paxillin is composed of two major 
domains; the N-terminus consisting of residues 1 through 325, and the C-terminus, which 
is composed of amino acids 326 to 559 (Turner, 2000).  The paxillin N-terminus contains 
two sites for tyrosine phosphorylation (residues 31 and 118) which, when activated 
provide binding sites for Src homology 2 (SH2) domain-containing proteins (Brown et 
al., 1996).  Additionally, the N-terminus provides binding sites various proteins such as 
FAK, vinculin, actopaxin, and SH3 domain-containing proteins (Brown et al., 1996; 
Nikolopoulos and Turner, 2000; Turner and Miller, 1994).  The C-terminus of paxillin 
contains four consecutive LIM domains which serve as binding sites for various proteins 












Figure 7.  Structure of Paxillin. 
Paxillin is composed of two major structural domains.  They are the N-terminal LD 
(leucine-aspartate) motifs 1-5 (note their sequence identity above), and the C-terminal 
LIM (Lin-11, Isl-1, Mec-3) domains.  Note the designated regions which are involved in 
binding to various proteins, such as FAK and vinculin.  Adapted from Turner, 2000. 
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al., 1999; Herreros et al., 2000).  Additionally, two of the LIM domains are responsible 
for targeting paxillin to FAs (Brown et al., 1996). 
A LIM domain is composed of cysteine/histidine-rich, coupled zinc fingers, 
which together constitute a zinc-coordinating domain (Bach, 2000).  Although they were 
originally thought to be DNA-interacting motifs, LIM domains are now known to 
function mainly as protein binding domains (Bach, 2000).  Of the four 50-amino acid 
LIM domains present in the C-terminus of paxillin, research shows that an intact LIM3 is 
essential for targeting paxillin to FAs (Brown et al., 1996).  Additionally, this same 
research demonstrates that a LIM2 double mutant decreases the efficiency of paxillin  
localization, which suggests that LIM2 might play a lesser but significant role in focal 
adhesion targeting (FAT).  Supporting this supposition, it has been shown that during cell 
adhesion or growth factor stimulation, phosphorylation of the threonine and serine 
residues on LIM2 and LIM3, respectively, increases the localization of paxillin to FAs 
(Brown et al., 1998).  Another study demonstrates that intact LIM3 and LIM4 domains 
are necessary for the binding of paxillin to the tyrosine phosphatase PTP-PEST at Pro 2, a 
novel proline-rich motif (Cote et al., 1999).  The same research suggests that PTP-PEST 
contributes to the removal of paxillin from FAs and therefore facilitates FA turnover, this 
because the LIM3 domain of paxillin is involved in both FA targeting and tyrosine 
phosphatase binding. 
Luecine-rich amino acid stretches with the general consensus sequence of LD X 
LL XX L are repeated five times within the N-terminus of paxillin (see Figure 7), and 
because of their conserved leucine (L) and aspartic acid (D) residues they have been 
named the LD motifs (Tumbarello et al., 2002).  Through modeling, the LD motifs have 
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been predicted to form amphipathic, α-helical structures with their leucine residues being 
arranged on one face of the helix, resulting in a hydrophobic protein-binding surface 
(Tumbarello et al., 2002).  LD motifs can be found in an extensive array of molecules 
ranging from structural proteins such as tensin (a FA protein) to regulatory proteins such 
as the guanine nucleotide-exchange factor Dbl (Brown et al., 1998).  Because the LD 
motifs of paxillin are evenly spaced within the N-terminus, it has been theorized that they 
function together to recruit various signaling partners into close proximity to better 
facilitate signal transmission (Tumbarello et al., 2002).  Multiple paxillin LD motifs have 
been found to bind the same protein; vinculin (a FA protein) binds to the LD1 
(LDALLADL) motif, as well as to LD2 (LDRLLLEL) and LD4 (LDELMASL) (Turner, 
2000).  Conversely, an individual LD motif can have multiple binding partners; LD1 
binds to both actopaxin and integrin-linked kinase (ILK) (Nikolopoulos and Turner, 
2000; Nikolopoulos and Turner, 2001).  Because of the similar characteristics of the 
paxillin LD motif binding partners, the theory that paxillin is involved with coordinating 
actin-cytoskeleton interactions has been reinforced (Turner, 2000).  Interestingly, paxillin 





A better understanding of the etiology of NF2 needs to be acquired in order to 
prevent and/or reverse its effects.  To achieve this goal, the mechanism of action of 
merlin’s negative growth regulating function in SCs must be elucidated.  A step in this 
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direction is to explore the molecular relationships between merlin and its various 
interactors within SCs. 
Previous research conducted in our laboratory demonstrated that merlin and 
paxillin associate in SCs (Obremski et al., 1998).  In order to determine the interaction 
type, direct binding assays were performed utilizing mixtures of various GST-merlin and 
GST-paxillin fusion proteins.  The results of these assays demonstrated that the binding 
between recombinant merlin and paxillin occurs in a direct manner, in vitro (Fernandez-
Valle et al., 2002).  Additionally, it was shown that merlin interacts directly with paxillin 
through two discrete domains that our laboratory has designated as PBD1 and PBD2, for 
paxillin binding domain 1 and paxillin binding domain 2.  Given these results, it would 
be of significance to determine which amino acid sequence(s) of paxillin bind to merlin. 
Merlin associates with β1 integrins in SCs, and this has been demonstrated by 
both co-localization studies and by co-immunoprecipitation experiments (Obremski et al., 
1998, Taylor et al., 2003).  These discoveries, coupled with research showing that the 
membrane-proximal region of the β1 integrin cytoplasmic domain associates with 
paxillin (Schaller et al., 1995), lead to the question of whether merlin binds directly to  
β1 integrin or associates with β1 integrin through paxillin. 
Merlin has been classified as an ERM family member based on a 49% overall 
homology to the other ERMs (Trofatter et al., 1993; Rouleau et al., 1993), and it has been 
shown to dimerize with its family member ezrin (Grönholm et al., 1999).  Based on this 
data, and because merlin has been shown to bind directly to paxillin (Fernandez-Valle et 
al., 2002), it would be valuable to determine possible interactions between ezrin and 
paxillin. 
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Given the background information presented here, this thesis explores the 
molecular relationships between merlin and its various interactors within SCs.  Therefore, 
the following questions will be addressed: 
1. What amino acid sequence(s) of paxillin bind to merlin? 
2. Does merlin bind directly to β1 integrin, or does it associate with β1 
integrin through paxillin? 
3. Do ezrin and paxillin associate with each other, and, if so, is the 





MATERIALS AND METHODS 
The following tables consist of lists of antibodies, reagents, and supplies that were 





Table 1.  Primary Antibodies. 
Antigen Vendor Host Species Dilution/Use 
β1 Integrincd BD Biosciences Mouse 1:100 / IB 
T7 Cell Signaling Mouse 1:2500 / IB 
GST Amersham Biosciences Goat 1:1000 / IB 
Merlin (C18) Santa Cruz Biotechnologies Rabbit 1:300 / IB 
Merlin (A19) Santa Cruz Biotechnologies Rabbit 1:200 / IB 
Paxillin BD Biosciences Mouse 1:10,000 / IB 
 
IB:  Immunoblot 
 
 
Table 2.  Secondary Antibodies. 
Conjugate Vendor Host Species Dilution/Use 
Peroxidase Jackson ImmunoReasearch Goat 1:20,000 / IB 
Peroxidase Jackson ImmunoReasearch Mouse 1:20,000 / IB 
Peroxidase Jackson ImmunoReasearch Rabbit 1:20,000 / IB 
 
IB:  Immunoblot 
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Table 3.  Additional Reagents and Supplies. 
Product Vendor Use 
LB medium Bio 101, Inc. Bacterial culturing 
LB agar Fisher Biotech Bacterial culturing 
Tryptone Fisher Biotech Bacterial culturing 
Yeast Fisher Biotech Bacterial culturing 
Ampicillin Sigma Bactericide 
Kanamycin Sigma Bactericide 
Isopropylthiogalactoside (IPTG) Sigma Protein induction 
Aprotinin Sigma Protease inhibitor 
Leupeptin Sigma Protease inhibitor 
ALLN (calpain) CalBiochem Protease inhibitor 
Sodium Pyrophosphate Sigma Protease inhibitor 
Phenylmethanesulfonyl Fluoride (PMSF) Sigma Protease inhibitor 
Sodium Fluoride (NaF) Sigma Protease inhibitor 
Sodium Orthovandanate (SOV) Sigma Protease inhibitor 
Complete EDTA-free PIC tablets Roche Protease inhibitor 
PIC (EDTA free for His-tagged) Sigma Protease inhibitor 
PIC (for GST-tagged) Sigma Protease inhibitor 
Immobilon-P PVDF membrane Millipore Western Blot 
Bovine Serum Albumin (BSA) Sigma Membrane blocking 
SuperSignal Chemiluminescent Reagent Pierce Western Blot 
GelCode Blue Stain Reagent Pierce Blue staining 
Silver Stain Kit BioRad Silver staining 
Tris-Acetate Fisher Biotech Buffer 
Sodium Choride (NaCl) MidWest Buffer/general 
Tris-HCl Fisher Biotech Buffer/SDS-PAGE 
Bis-Acrylamide BioRad SDS-PAGE 
Sodium dodecyl sulfate (SDS) Amresco Buffer/SDS-PAGE 
Ammonium Persulfate (APS) Amresco SDS-PAGE 
TEMED BioRad SDS-PAGE 
Molecular Weight Markers BioRad SDS-PAGE 
Agarose Amresco DNA gels 
Hyperladder Bioline DNA marker 
NP 40 Sigma Buffer 
Glycerol Sigma General 
Triton X-100 Sigma Protein purification 
Lysozyme Sigma Protein purification 
Benzonase Nuclease Novagen Protein purification 
Imidazole Sigma Protein purification 
BamHI Invitrogen Restriction digestion 
EcoRI Invitrogen Restriction digestion 
SmaI Invitrogen Restriction digestion 
XhoI Invitrogen Restriction digestion 
T4 DNA Ligase Promega DNA ligation 
Shrimp Akaline Phosphotase (SAP) USB Corp. Cloning 
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Product Vendor Use 
Cell culture dishes Corning Cell culture 
Fetal Bovine Serum (FBS) Hyclone Cell culture 
Forskolin Sigma Cell culture 
Pituitary Extract (PEX)  Biomed. Tech Cell culture 
Dulbecco’s Modified Eagle Medium (DMEM) Life Tech. Cell culture 
Hanks Balanced Salt Solution Life Tech. Cell culture 
Phosphate buffered saline (PBS) Gibco Cell culture 
GST Bind/Wash Buffer Novagen Protein purification 
GST Elution Buffer  Novagen Protein purification 
Glutathione Sepharose 4B Beads Amersham Protein purification 
Ethanol Sigma General 







Frozen SCs, obtained from previous sciatic nerve dissections of newborn 
Sprague-Dawley rats (Charles River, Raleigh, NC) (Brockes et al., 1979), were thawed 
and then plated on PLL (200µg/ml)-coated tissue culture dishes.  Cells were grown in 
DMEM containing 10% FBS, 20µg/ml PEX, and 2µM forskolin until used in 
experiments.  Cells were passaged no more than six times. 
 
Schwann Cell Protein Extraction 
 
Medium was removed from the SC cultures, and then the cultures were rinsed 
twice with cold PBS.  Cultures were incubated on ice in TAN buffer (10mM Tris-acetate 
pH 8, 100mM NaCl, 1%NP-40) containing protease and phosphatase inhibitors (20µg/ml 
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aprotinin, 10µg/ml luepeptin, 1mM SOV, 1mM sodium pyrophospate, 50mM NaF, 2mM 
PMSF) for 20 minutes (min).  Cells were removed from the culture dish using a rubber 
policeman, and the solution was pipetted into a pre-chilled Eppendorf tube.  The cell 
suspension was vortexed for 2 min, incubated for 15 min at 4°C while rotating, and was 
then centrifuged in an Eppendorf 5417C at 14,000rpm for 15 min at 4°C.  The 
supernatant containing the protein lysate was removed and stored at -80°C until further 
use.  The cellular debris pellet was also stored at -80°C until the completion of the 
experiment.  Protein concentrations were determined for the lysate using the Bio-Rad DC 
Protein assay (modified Lowry assay). 
 
Electro-competent Bacteria Production 
 
Electro-competent bacteria were produced for use in cloning.  Three cultures of 
each the BL21 (expression), BL21(DE3) (expression), and XL1Blue (cloning) empty 
plasmids were prepared using 4ml of SOB medium (without Mg2+, without antibiotics), 
and were incubated overnight (~ 16 hrs) at 37°C.  The cultures were expanded to 50ml, 
and grown until an optical density (OD) reading of 0.4 to 0.5.  The cultures were then 
aliquoted into pre-chilled tubes and centrifuged at 5000rpm for 10 min at 4°C.  The 
supernatant was discarded, and the pellets were resuspended in 25ml of sterilized, ice-
cold 10% glycerol.  The cultures were centrifuged at 5000rpm for 15 min at 4°C and the 
supernatant was immediately removed.  The glycerol wash step was repeated an 
additional time, and the supernatant was removed.  The remaining bacterial slurry for 
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each plasmid was aliquoted (40µl) into pre-chilled micro-centrifuge tubes and then flash-
frozen in a dry ice/ethanol bath.  These were then stored at -80°C. 
The competent bacteria were tested by electroporation to determine if they had 
been washed enough; they had.  An aliquot of cells was transformed with pGEX-6P as a 
positive control.  Samples of the competent bacteria were plated on agar containing 
antibiotics and incubated overnight at 37°C.  The three competent bacterial strains 
showed no colony growth, as they shouldn’t, because they had no plasmids and therefore 
no antibiotic resistance.  The positive control colony did show growth, as it should 
because the pGEX plasmid confers ampicillin resistance.  Colony growth verified that the 
electro-competent bacteria were acceptable. 
 
Generation of His-Merlin Constructs 
 
His-merlin-N term (NT) and His-merlin-C term (CT) glycerol stocks were 
available from earlier research conducted in our laboratory.  Sub-cloning was necessary 
to generate the additional two His-tagged merlin constructs required for this thesis 
research. 
Cultures of 30ml LB broth and ampicillin (30µl) were begun using either BL21, 
XL1-Blue, or DH5α strains of bacterial glycerol stocks containing plasmids with the 
insert sequences merlin-NT∆PBD1 (merlin without the PBD1 sequence) and merlin-
CT∆PBD2 (merlin without PBD2).  Following overnight incubation, the plasmids were 
purified from the bacterial cultures using the QIAGEN Plasmid Purification Midi Kit.  
The resulting plasmid DNA was resuspended in 150µl of milli-pore water (mp), and OD 
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readings were performed in order to determine the amount of each plasmid DNA 
obtained. 
Digestion reactions were set up to cut each insert from its plasmid DNA using 
BamHI (5µl) and EcoRI (5µl) restriction enzymes (REs).  The 25µg-plasmid DNA 
reaction mixtures were digested overnight in a 37°C liquid incubator.  In order to separate 
each insert DNA from its plasmid DNA, the digestion mixtures were run on a 1% agarose 
gel.  Additionally, a sample of the pre-cut and de-phosphorylated pET-28a(+) plasmid 
was run to verify that it had been previously cut.  Using an ultraviolet (UV) light, the size 
of each insert DNA was confirmed. 
The merlin inserts were purified out of the gel using the QIAquick Gel Extraction 
Kit, and then OD readings were performed to determine the DNA amounts obtained.  
Ligation mixtures, consisting of 30 femto-moles (f-mol) of each DNA, were set up using 
T4 Ligase to anneal each merlin insert into its pET vector.  The reaction mixtures were 
incubated overnight in a 16°C liquid bath.  Following incubation, the DNA was 
precipitated out of solution using 1-butanol followed by ethanol, and was then re-
suspended in mp water (10µl). 
Each insert-containing plasmid (1µl) was used in the transformation of both 
XL1Blue and BL21DE3 electro-competent bacteria.  The bacteria were transformed 
using the Gene Pulser (200Ω, 25µF, 1.80V), were incubated in SOC medium for 1 hr, 
and were then spread (30 to 50µl) onto warm agar plates.  The agar plates contained 
kanamycin (50µl/ml) for the selection of positive clones, and the plates were incubated 
overnight at 37°C. 
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Following incubation, 5ml LB broth cultures containing kanamycin (final conc. of 
50µl/ml) were begun using colonies picked from both the XL1Blue and BL21DE3 agar 
plates.  These cultures were incubated overnight at 37°C, and the following day 3ml of 
each culture was purified for plasmid using the QIAprep Spin Miniprep Kit.  Each 
plasmid was then digested with both EcoRI and BamHI restriction enzymes, and the 
digestions were run on a 1% agarose gel to confirm presence of the inserts.  As seen in 
Figure 8, construction of positive clones was confirmed.  Finally, gycerol stocks were 




Affinity Pull-down Assay (Indirect Binding) 
 
SCs were grown to confluency and the total protein was extracted, as previously 
described.  GST and GST-paxillin fusion proteins (0.5µg) were immobilized onto 50µl 
(bed volume) of Glutathione Sepharose 4B beads.  The beads were brought up to 1ml 
with TAN extraction buffer, and were then incubated for 30min with rocking at RT.  
Following incubation, the samples were centrifuged at 500g for 5 min and the supernatant 
was removed.  SC lysate, 200µg, was added to the immobilized GST-paxillin fusion 
proteins.  The samples were incubated O/N at 4°C while rocking.  Following incubation, 















Figure 8.  Confirmation of Positive His-Merlin Clones. 
The transformed bacteria were plated on agar and incubated overnight at 37°C.  
Overnight cultures were set up with bacterial colonies picked from the agar plates for 
each merlin insert, and these were incubated overnight at 37°C.  Plasmid DNA was 
purified from the cultures, the plasmids were digested with BamHI and EcoRI restriction 
enzymes, and the digestion solutions were resolved on a 1% agarose gel to confirm the 
presence of the merlin-N∆PBD1 and -C∆PBD2 inserts.  His-merlin-NT∆PBD1 insert 
presence was confirmed in 4 clones of each XL1Blue and BL21DE3 at the approximated 
size of 890 bp (A).  His-merlin-CT∆PBD2 insert presence was confirmed in 4 clones of 
each XL1Blue and BL21DE3 at the approximated size of 890 bp (B).  
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1X GST Bind/Wash Buffer containing 0.1% TX-100.  Following the rinses, the beads 
were resuspended in 40µl of 3X SDS sample buffer, and were boiled at 100°C for 10 
min.  Western blot analysis then followed. 
 
Direct Binding Assays 
 
In general, the various GST-tagged fusion proteins (0.25µg) were immobilized 
onto 20µl (bed volume) of Glutathione Sepharose 4B beads.  The beads were brought up 
to 1ml with 1X PBS containing 0.1% TX-100, and were then incubated for at least 2 hr at 
4°C while rocking.  Following incubation, the samples were centrifuged at 500g for 5 
min at 4°C, and the supernatant was removed and saved.  The beads were rinsed 2 times 
with 1X PBS containing 0.1% TX-100; the rinse fractions were saved.  The various His-
tagged fusion proteins (0.25µg) were then added to the beads, and the buffer (1X PBS 
containing 0.1% TX-100 and 500mM NaCl) was brought up to 1ml.  The samples were 
incubated O/N at 4°C while rocking.  Following incubation, the beads were centrifuged at 
500g for 5 min at 4°C, and the supernatant was removed and saved.  The samples were 
rinsed 3 times with 1X PBS containing 0.1% TX-100 and 500mM NaCl.  Following the 
rinses, the beads were resuspended in 40µl of 5X SDS sample buffer, and were boiled at 






Western Blot Analysis 
 
Protein samples, which had already been resuspended in SDS Sample buffer, 
were boiled for 3 min at 100°C to ensure denaturization, and were then resolved by 
sodium dodecyl sufate-polyacrylamide gel electrophoresis (SDS-PAGE).  The smaller 
recombinant proteins were run on 12% gels for better seperation, while the larger 
recombinant proteins were run on either 8% or 10% gels.  Immediately following SDS-
PAGE, the proteins were electroblotted onto PVDF membranes.  Membranes were 
stained with India ink that was diluted 1:1000 in TBS-T.  Membranes were then blocked 
for 1hr at RT in either 5% powdered milk in TBS-T (blocking buffer) or in TBS-T alone 
depending on the primary antibody used.  Membranes were then incubated with the 
indicated primary antibodies diluted in the appropriate blocking buffer on a surf blot 
apparatus for 1hr at RT.  After rinsing multiple times in TBS-T, the membranes were 
incubated with the indicated HRP-conjugated secondary antibodies for 30 min at RT.  
Membranes were exposed to SuperSignal Chemiluminescent reagents.  Detection of 
proteins was performed using Kodak X-ray film placed over the membranes for various 




Recombinant Protein Expression and Purification 
 
GST-Paxillin Fusion Proteins 
 
The GST-paxillin-full length (FL), GST-paxillin-N term (NT), and GST-paxillin-
C term (CT) fusion proteins were generated from the pGEX-6P plasmid.  The GST-
paxillin-LD fusion proteins were generated from bacterial colonies transformed with the 
pGEX-2TK plasmid received as a gift from Dr. C. Turner of SUNY Upstate Medical 
University in Syracuse, New York.  The pGEX plasmid was used to confer a glutathione 
S-transferase (GST) tag onto the N-terminus of the recombinant protein produced from 
the bacterial cultures. 
Starting with 4ml of LB broth, cultures were begun using previously prepared 
glycerol stocks of transformed BL21 bacteria containing each construct of interest.  
Ampicillin was added (final concentration of 100µg/ml) to the cultures in order to select 
for transformed bacteria.  The cultures were incubated at 37°C, overnight, with shaking at 
300rpm for aeration.  Following incubation, the bacterial cultures were expanded by 
adding 2YT broth to a 30ml final volume; again, ampicillin was added (30µl).  The 
bacterial cultures were grown until an OD reading of 0.6 to 0.8 was reached.  
Recombinant protein expression was induced using IPTG (final concentration of 1 mM).  
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The bacterial cultures were then incubated at 30 to 37°C for between 2 to 6 hrs with 
shaking at 250 rpm for aeration.  The ranges given for induction temperature and time are 
dependant upon the specific paxillin construct.  Following incubation, the bacteria were 
pelleted at 6000rcf for 20 min at 4°C.  The supernatant was removed, and each pellet was 
either immediately utilized or stored at -80°C until use. 
If previously frozen, the bacterial pellets were thawed on ice.  Each pellet was 
resuspended in 1ml of GST lysis buffer (10mM Tris-HCl, pH 8.0, 100µl PIC, 1% TX-
100).  Lysozyme (1mg/30ml pellet) was added and the suspension was incubated for 15 
min on ice.  Bacterial lysis was obtained either by French press (2 times at 700psi) or by 
sonication (3 times at 10 sec each time followed by 30 sec pauses).  The resulting lysate 
was centrifuged at 14,000rpm for 20 min at 4°C.  The supernatants containing the 
recombinant proteins were transferred to pre-chilled Eppendorf tubes, and were either 
used immediately or stored at -20°C. 
Purification of the recombinant GST-tagged paxillin proteins was done in batch 
using Glutathione Sepharose 4B beads (50µl bed volume/sample), which were rinsed 2 
times with 1X PBS prior to use.  The beads were added to the lysates, and the samples 
were incubated overnight at 4°C while rotating.  Following incubation, the samples were 
centrifuged at 500g for 5 min, and the supernatant was removed and stored.  To remove 
remaining impurities, the beads were rinsed 3 times in 1X GST Bind/Wash Buffer.  
Following the final rinse, the beads were resuspended in 200µl of 1X GST Elution Buffer 
(50mM Tris-HCl, 10mM reduced glutathione) with 0.1% TX-100.  To elute the purified 
proteins from the beads, the samples were incubated at 4°C while rotating.  After 30 min, 
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the samples were centrifuged at 510g for 5 min at 4°C and the supernatants containing 
the purified recombinant proteins were collected. 
Protein concentrations were determined using either the modified Lowry assay or 
the Bio-Rad Protein Assay (modified Bradford assay).  The recombinant proteins were 
resolved using SDS-PAGE, and were Blue Stained to verify their presence and to 
determine their relative purity.  Figure 9 shows the expressed and purified GST-paxillin 
LD fusion proteins. 
 
His-Paxillin Fusion Proteins 
 
The His-paxillin-full length (FL) fusion protein was generated from the pET-
28a(+) plasmid, which confers a His tag to the N-terminus of the recombinant protein 
produced.  Starting with 5ml of LB broth, the culture was begun using a previously 
prepared glycerol stock of BL21DE3 bacteria.  Kanamycin was added (final 
concentration of 50µg/ml) to the culture to select for transformed bacteria.  The culture 
was incubated at 37°C overnight, with shaking at 300rpm for aeration.  Following 
incubation, the culture was expanded by adding LB broth to a 30ml final volume; again, 
kanamycin was added (30µl).  The culture was grown until an OD reading of 0.6 to 0.8 
was reached.  Recombinant protein expression was induced using IPTG (final 
concentration of 1mM).  The culture was incubated at 32°C for 4 hrs with shaking at 
250rpm for aeration.  Following incubation, the bacteria were pelleted at 6000rcf for 20 




















Figure 9.  Expression and Purification of GST-Paxillin Fusion Proteins. 
Overnight bacterial cultures were expanded until an OD of 0.6 to 0.8, and then expression 
was induced with 1mM IPTG for 4 hrs at 30°C in the presence of ampicillin.  Pelleted 
bacteria were lysed by sonication and purified in batch using Glutathione Sepharose 4B 
beads.  Proteins were eluted with 1X GST Elution Buffer in 200µl aliquots.  Protein 
concentration was determined by the modified Lowry assay.  The recombinant proteins 




The frozen pellet was thawed on ice, and then resuspended in 5ml of bind buffer 
(0.02M sodium phosphate, 0.5M NaCl, pH 7.4).  Lysozyme (1mg/ml) was added and the 
solution was incubated on ice for 30 min, followed by sonication.  Benzonase (1µl) was 
added and the solution was incubated for an additional 30 min on ice.  The solution was 
centrifuged at 14,000rpm for 20 min at 4°C, and the supernatant was saved as the crude 
lysate. 
The His-paxillin-FL fusion proteins were purified using the Amersham 
Biosciences HiTrap Chelating HP column, charged with 0.1M NiSO4 in distilled water, 
according to the manufacturer’s instructions.  Briefly, the chelating column was washed 
with distilled water, charged with the NiSO4 solution, washed again with water, and then 
equilibrated with bind buffer.  Immediately prior to application, the crude lysate was 
passed through a 0.45µm PES filter for clarification.  The lysate was applied to the 
column with a syringe, and the column was rinsed with bind buffer containing 5mM of 
imidazole.  The proteins were eluted from the column, in one step, using elution buffer 
(0.02M sodium phosphate, 0.5M NaCl, 0.5M imidazole, pH 7.4). 
The concentration was determined using the Bradford assay, and the purified 
protein was resolved using SDS-PAGE.  The gel was then Blue Stained to verify the 
presence of His-paxillin and to determine its relative purity.  Figure 10 shows the two 
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Figure 10.  Expression and Purification of the His-Paxillin Fusion Protein. 
Overnight bacterial cultures were expanded until an OD of 0.6 to 0.8.  Bacterial 
expression of the recombinant protein was induced with 1mM IPTG for 4 hrs at 32°C in 
the presence of kanamycin.  Pelleted bacteria were lysed by sonication and purified using 
Amersham Biosciences HiTrap Chelating HP columns charged with 0.1M NiSO4.  
Proteins were eluted with 0.02M sodium phosphate, 0.5M NaCl, 0.5M imidazole, pH 7.4, 
and protein concentration was determined by the Bradford assay.  The recombinant 




His-Merlin Fusion Proteins 
 
Expression of the merlin constructs was begun with 4ml of LB broth, to which 
was added the transformed bacteria containing each construct of interest and kanamycin 
(final concentration of 50µg/ml).  The cultures were incubated at 37°C, overnight, with 
shaking at 300rpm for aeration.  Following incubation, the bacterial cultures were 
expanded by adding LB broth to a 30ml final volume; again, kanamycin was added 
(30µl).  The bacterial cultures were grown until an OD reading of 0.6 to 0.8 was reached.  
Recombinant protein expression was induced using IPTG (final concentration of 1 mM).  
The bacterial cultures were then incubated at 33°C for 4 hrs with shaking at 250rpm for 
aeration.  Following incubation, the bacteria were pelleted at 6000rcf for 20 min at 4°C.  
The supernatant was removed, and each pellet was either immediately utilized or stored 
at -80°C until use. 
If previously frozen, the bacterial pellets were thawed on ice.  The His-tagged 
merlin constructs were purified using the QIAGEN Ni-NTA Spin Kit according to the 
manufacturer’s instructions.  Briefly, each pellet was resuspended in lml of lysis buffer 
(50mM NaH2PO4, 300mM NaCl, 10mM imidazole, pH 8.0).  Lysozyme (1mg/30ml 
pellet) was added and the suspension was incubated for 30 min on ice.  During 
incubation, one tablet of Complete EDTA-free PIC (protease inhibitor cocktail) was 
added to the suspension.  Bacterial lysis was obtained by sonication, and the resulting 
lysate was centrifuged at 14,000rpm for 20 to 30 min at 4°C.  The supernatants 
containing the recombinant proteins were transferred to pre-chilled Eppendorf tubes, and 
were either used immediately or stored at -20°C.  The Ni-NTA spin columns were 
 44
equilibrated with lysis buffer, and the cleared lysates were added to the columns.  The 
spin columns were centrifuged for 2 to 4 min at 700g, followed by collection of the flow-
through.  The spin columns were washed 4 times with wash buffer (50mM NaH2PO4, 
300mM NaCl, 20mM imidazole, pH 8.0) to remove non-specific proteins.  The His-
tagged merlin proteins were then eluted off the columns 3 times using elution buffer (50 
mM NaH2PO4, 300mM NaCl, 250mM imidazole, pH 8.0).  The purified recombinant 
proteins were collected in 200µl aliquots, and the protein concentrations were determined 
using the Bradford assay.  The recombinant proteins were resolved using SDS-PAGE, 
and were immuno-blotted to verify their presence and to determine their relative purity.  
Figure 11 displays the purified merlin fusion proteins. 
 
GST-Ezrin Fusion Proteins 
 
The ezrin recombinant proteins were prepared from ezrin cDNAs received as a 
gift from Dr. O. Carpén of the University of Helsinki in Finland.  The ezrin-NT (1-309) 
insert was received in the pGEX-4T-1 plasmid; the restriction enzymes used in its 
cloning were EcoRI and (BamHI, SmaI, and SalI).  The ezrin-CT insert was received in 
the pGEX-4T-3 plasmid, and its restriction enzyme sites were SmaI and XhoI. 
Each cDNA (1µl) was used to transform both XL1Blue and BL21 electro-
competent bacteria.  The bacteria were transformed using the Gene Pulser (200Ω, 25µF, 
1.80V), and were incubated in SOC medium for 1 hr.  The cultures were spread (50µl) 
onto warm agar plates containing ampicillin (100µg/ml) for the selection of positive 
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Figure 11.  Expression and Purification of the His-Merlin Fusion Proteins. 
Overnight bacterial cultures were expanded until an OD of 0.6 to 0.8.  Bacterial 
expression of the recombinant proteins was induced with 1mM IPTG for 4 hrs at 32°C in 
the presence of kanamycin.  Pelleted bacteria were lysed by sonication and purified using 
the QIAGEN Ni-NTA Spin Kit.  Proteins were eluted with 50mM NaH2PO4, 300mM 
NaCl, 250mM imidazole, pH 8.0, and protein concentration was determined by the 
Bradford assay.  The recombinant proteins were resolved by SDS-PAGE (12%), and 
were analyzed by Western Blot to determine their relative purity. 
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Starting with 4ml of LB broth and ampicillin (final concentration of 100µg/ml), 
cultures were begun using colonies picked from the BL21 agar plates containing each 
insert of interest.  The cultures were incubated at 37°C, overnight, with shaking at 300 
rpm for aeration.  Following incubation, the bacterial cultures were expanded by adding 
2YT broth to a 50ml final volume; again, ampicillin was added (50µl).  The bacterial 
cultures were grown until an OD reading of 0.6 to 0.8 was obtained.  Protein expression 
was induced using IPTG (final concentration of 1mM), and the bacterial cultures were 
incubated at 35°C for 5 hrs with shaking at 250rpm for aeration.  Following incubation, 
the bacteria were pelleted at 6000rcf for 20 min at 4°C.  The supernatant was removed, 
and each pellet was either immediately utilized or stored at -80°C until use. 
If previously frozen, the bacterial pellets were thawed on ice.  Each pellet was 
resuspended in 3.5ml of GST lysis buffer (10mM Tris-HCl, pH 8.0, 100µl PIC, 1% TX-
100, 2mM PMSF).  Lysozyme (1mg/30ml pellet) was added and the suspension was 
incubated for 30 min on ice.  Bacterial lysis was obtained by sonication (3 times at 10 sec 
each time followed by 30 sec pauses).  The resulting lysate was centrifuged at 14,000 
rpm for 20 min at 4°C.  The supernatants containing the recombinant proteins were 
transferred to pre-chilled Eppendorf tubes, and were either used immediately or stored at 
-20°C. 
Purification of the GST-tagged ezrin fusion proteins was completed, in batch, 
using Glutathione Sepharose 4B beads (50µl bed volume/sample), which were rinsed 2 
times with 1X PBS prior to use.  The beads were added to the lysates, and the samples 
were incubated 1.5 hrs at 4°C while rotating.  Following incubation, the samples were 
centrifuged at 500g for 5 min, and the supernatant was removed and stored.  To remove 
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remaining impurities, the beads were rinsed 3 times in 1X GST Bind/Wash Buffer.  
Following the final rinse, the beads were resuspended in 200µl of 1X GST Elution Buffer 
(50mM Tris-HCl, 10mM reduced glutathione) with 0.1% TX-100, and the samples were 
incubated at 4°C while rotating.  After 30 min, the samples were centrifuged at 510g for 
5 min at 4°C and the supernatants containing the purified recombinant proteins were 
collected. 
Protein concentrations were determined using the Bradford assay.  The 
recombinant proteins were resolved using SDS-PAGE, and were Blue Stained to verify 
their presence and to determine their relative purity (Figure 12). 
 
GST-β1 Integrin Cytoplasmic Domain (CD) Fusion Proteins 
 
The GST-β1 integrin CD (GST-β1cd) fusion protein was generated from the 
pGEX-2TK plasmid.  Starting with 5ml of LB broth, the culture was begun using a 
previously prepared glycerol stock of transformed BL21 bacteria containing the insert of 
interest.  Ampicillin was added (final concentration of 100µg/ml) to the culture in order 
to select for transformed bacteria.  The culture was incubated at 37°C, overnight, with 
shaking at 300rpm for aeration.  Following incubation, the bacterial culture was expanded 
by adding 2YT broth to a 45ml final volume; again, ampicillin was added (45µl).  The 
culture was grown until an OD reading of 0.6 to 0.8 was reached, and recombinant 
protein expression was induced using IPTG (final concentration of 1mM).  The culture 














Figure 12.  Expression and Purification of GST-Ezrin Fusion Proteins. 
cDNA (1µl) for each construct was used to transform BL21 and XL1Blue bacteria using 
electroporation, and the transformed bacteria were plated on agar containing ampicillin 
(100µg/µl) and incubated overnight at 37°C.  Overnight cultures were set up with 
bacterial colonies picked from the agar plates for each ezrin construct, and these were 
incubated overnight at 37°C.  Overnight bacterial cultures were expanded until an OD of 
0.6 to 0.8, and bacterial expression of the recombinant proteins was induced with 1mM 
IPTG for 5 hrs at 35°C in the presence of ampicillin.  Pelleted bacteria were lysed by 
sonication and purified in batch using Glutathione Sepharose 4B beads.  Proteins were 
eluted with 1X GST Elution Buffer in 200µl aliquots.  Protein concentrations were 
determined by the Bradford assay.  The recombinant proteins were resolved by SDS-






incubation, the bacteria were pelleted at 6000rcf for 20 min at 4°C.  The supernatant was 
removed, and each pellet was either immediately utilized or stored at -80°C until use. 
If previously frozen, the bacterial pellets were thawed on ice.  Each pellet was 
resuspended in 1.25ml of lysis buffer (20mM Tris-HCl, pH 8.0, 300mM NaCl, 1% TX-
100, 100µl PIC, 1mM Na pyrophosphate, 50mM NaF, 1mM SOV, 2mM PMSF).  
Lysozyme (1mg/30ml pellet) was added and the suspension was incubated for 30 min on 
ice.  Bacterial lysis was obtained by sonication (3 times at 10 sec each time followed by 
30 sec pauses), and the resulting lysates were centrifuged at 14,000rpm for 15 min at 
4°C.  The supernatants containing the recombinant proteins were transferred to pre-
chilled Eppendorf tubes, and were either used immediately or stored at -80°C. 
Purification of the GST-β1cd fusion protein was completed utilizing Amersham 
Biosciences Glutathione Sepharose 4B Microspin columns.  Briefly, the columns were 
vortexed to resuspend the resin, and were centrifuged to remove the storage buffer.  The 
lysates (600µl) were added to the columns and the samples were rocked at room 
temperature (RT) for 10 min.  Following incubation, the samples were centrifuged at 
735g for 1 min, and the supernatant was removed and stored.  To remove remaining 
impurities, the columns were rinsed 3 times with 1X PBS containing 0.1% TX-100.  The 
recombinant protein was eluted from the columns 2 times in 200µl of Glutathione Elution 
Buffer (50mM Tris-HCl, 10mM reduced glutathione) with 0.1% TX-100.  Each elution 
was incubated for 15 min at 4°C while rocking, and the columns were centrifuged at 
735g for 1min at 4°C to collect the eluates.  The GST-β1cd fusion protein concentrations 
were determined using the Bradford assay.  The recombinant proteins were resolved 
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using SDS-PAGE, and the gel was Blue Stained, as seen in Figure 13, to verify the 
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Figure 13.  Expression and Purification of the GST-β1cd Fusion Proteins. 
Overnight bacterial cultures were expanded until an OD of 0.6 to 0.8.  Bacterial 
expression of the recombinant protein was induced with 1mM IPTG for 4 hrs at 30°C 
in the presence of ampicillin.  Pelleted bacteria were lysed by sonication and purified 
using Amersham Biosciences Glutathione Sepharose 4B Microspin columns.  Proteins 
were eluted with 1X GST Elution Buffer in 200µl aliquots.  Protein concentration was 
determined by the Bradford assay.  The recombinant proteins were resolved by SDS-






Affinity Pull-down Assay (Indirect Binding) 
 
Previous studies conducted in this laboratory demonstrate that merlin and paxillin 
bind in a direct manner, in vitro (Fernandez-Valle et al., 2002).  Subsequent research 
revealed that merlin interacts with paxillin through two discrete domains designated as 
PBD1 and PBD2, for paxillin binding domain 1 and paxillin binding domain 2 
(Fernandez-Valle et al., 2002).  It follows that the binding site(s) for merlin on the 
paxillin protein should be identified.  The first experiment conducted toward this end was 
an affinity pull-down assay.  Various GST-paxillin fusion proteins were produced as 
described previously.  The paxillin fusion proteins were immobilized onto Glutathione 
Sepharose beads and were then mixed with confluent SC lysate, obtained as described in 
the Materials and Methods section.  Following incubation and rinsing, the samples were 
analyzed by Western blot utilizing merlin and GST antibodies. 
As seen in the total extract (TE) lane of Figure 14, endogenous merlin migrates at 
~ 68 kDa when detected with merlin antibody; this lane was used as a reference for 
merlin presence in the binding assays.  Merlin was detected in both the GST-pax-FL and 
GST-pax-NT lanes, indicating that endogenous merlin is able to bind both full-length 
paxillin and the N-terminus of paxillin, in vitro.  An additional band of approximately 48 




































Figure 14.  GST-Paxillin Full-Length and N-Terminus Bind to Merlin From 
Confluent Schwann Cell Lysate. 
SCs were grown to confluency and the total protein was extracted.  GST and GST-
paxillin fusion proteins (0.5µg), immobilized on glutathione sepharose beads, were 
incubated with 200µg of SC lysate.  The samples were resolved by SDS-PAGE (10%) 
and then immunoblotted with rabbit anti-merlin antibody (C18). The bands present at 
68kDa in the GST-pax-FL and GST-pax-NT lanes indicate that merlin binds to full 
length paxillin as well as the N-terminus of paxillin, in vitro.  The 48kDa bands detected 
in the GST-pax-FL and GST-pax-NT lanes are most likely merlin cleavage products.  
Total extract (TE) serves as a positive control verifying the presence and molecular 
weigh of the endogenous merlin in the SC lysate. 
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research has shown that when utilizing the merlin C18 antibody in Western blot analysis 
of SC lysates, up to four bands (120, 88, 68, and 48 kDa) of merlin can be detected (Chen 
et al., 2000), with the 68 kDa band being regarded as the wild-type (Shaw et al., 1998b).  
The faster migrating 48 kDa band is most likely a cleavage product of merlin, as studies 
have shown that calpain cleaves merlin and therefore results in numerous cleavage 
products which can be detected by the C18 antibody (Kimura et al., 2000).  The 48 kDa 
band was not detected in the TE lane, indicating a relatively lower abundance of merlin 
cleavage products in the SC extract as compared to that of the total protein.  No merlin 
was detected in the GST-pax-CT lane, suggesting that merlin does not bind to the C-
terminus of paxillin, in vitro.  Additionally, merlin was not detected in the GST-beads 
control lane, indicating that merlin binding to the paxillin fusion proteins was not the 
result of non-specific binding to either the GST-tag or the beads themselves. 
 
Direct Binding Assays 
 
The results of the previous experiment suggested that binding interactions 
between merlin and paxillin should be focused on just the N-terminus of paxillin.  To 
determine which paxillin amino acid residues directly facilitate the merlin-paxillin 
interaction, direct binding assays were conducted between the N-terminal GST-paxillin 
LD fusion proteins and the His-tagged merlin fusion proteins.  The paxillin and merlin 
fusion proteins were produced as described previously.  The GST-paxillin fusion proteins 
were immobilized onto Glutathione Sepharose beads, and then the His-tagged merlin 
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fusion proteins were added to the buffer.  Following incubation and rinsing, the samples 
were analyzed by Western blot using merlin and GST antibodies. 
Figure 15A shows that merlin was detected (via the A19 antibody) in the GST-
pax-LD3 lane, indicating that the N-terminus of merlin binds to the paxillin LD3motif, in 
vitro.  Additionally, merlin was detected in the GST-pax-LD4 and -LD5 lanes, indicating 
that the N-terminus of merlin also binds to paxillin LD4 and LD5, but to a lesser extent.  
As revealed in Figure 16A, when utilizing the C18 antibody, merlin was differentially 
detected as binding to paxillin LD motifs 2 through 5.  Specifically, the C-terminus of 
merlin exhibited strong binding to paxillin domains LD2 and LD3, in vitro.  Merlin was 
also detected in the GST-pax-LD4 and -LD5 lanes.  This indicates that, as with the N-
terminus, the C-terminus of merlin binds paxillin LD4 and LD5, but with a weaker 
affinity than with domains LD2 and LD3.  Neither of the merlin fusion proteins were 
detected in the GST-pax-LD1 lane, suggesting that merlin does not bind to paxillin LD1, 
in vitro.  Additionally, no merlin was detected in either of the GST-beads or beads-alone 
control lanes, indicating that merlin binding to the recombinant paxillin proteins was not 
the result of non-specific binding to either the GST-tag or the beads themselves.  To 
demonstrate equal loading of the GST-paxillin fusion proteins, the membranes were 
stripped and re-blotted with the GST antibody.  Figures 15B and 16B demonstrate equal 
loading for each paxillin LD fusion protein present in each binding assay. 
The results from the previous experiments conducted for this thesis suggested 
that, due to its interactions with both the amino and carboxy termini of merlin, the 












































































Figure 15.  GST-Paxillin-LD3 Binds Directly to His-Merlin N-Terminus. 
GST and GST-paxillin fusion proteins (0.25µg), immobilized on glutathione sepharose 
beads, were incubated with His-merlin N term fusion proteins (0.25µg).  The samples 
were resolved by SDS-PAGE (12%), and Western blot analyses were performed utilizing 
rabbit anti-merlin antibodies.  Recombinant His-mer-NT was run to verify its molecular 
weight as detected by the merlin A19 antibody.  The band present in the GST-pax-LD3 
lane indicates that the merlin N-terminus binds directly to paxillin at LD domain 3, in 
vitro.  Weaker binding was detected at LD domains 4 and 5 (A).  Following the initial 
blotting, the membrane was stripped and re-probed with goat anti-GST to show equal 




































































Figure 16.  GST-Paxillin-LDs 2 and 3, Predominantly, Bind Directly to His-Merlin 
C-Terminus. 
GST-paxillin fusion proteins (0.25µg), immobilized on glutathione sepharose beads, were 
incubated with His-merlin C term fusion proteins (0.25µg).  The samples were resolved 
by SDS-PAGE (12%), and Western blot analyses were performed utilizing rabbit anti-
merlin antibodies.  Recombinant His-mer-CT was run to verify its molecular weight as 
detected by the merlin C18 antibody.  The bands present in the GST-pax -LD2 and -LD3 
lanes indicate that the merlin C-terminus binds directly and predominantly to paxillin at 
LD domains 2 and 3, in vitro.  Weaker binding was detected at LD domains 4 and 5 (A).  
Following the initial blotting, the membrane was stripped and re-probed with goat anti-
GST to demonstrate equal loading of the GST-paxillin fusion proteins (B). 
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Additionally, previous studies conducted in this laboratory have shown that the merlin 
PBD1 domain binds directly with paxillin.  Taken together, these results suggest that the 
paxillin LD3 and merlin PBD1 sequences are essential for direct binding between paxillin 
and merlin.  To determine the validity of this hypothesis, a final and specific direct 
binding assay was conducted.  Recombinant His-tagged merlin lacking the PBD1 
sequence, His-mer-NT∆PBD1, was produced as described previously.  The GST-pax-
LD3 fusion proteins were immobilized onto Glutathione Sepharose beads, and then both 
of the His-mer-NT and His-mer-NT∆PBD1 fusion proteins were added to the buffer 
solutions.  Following incubation and rinsing, the samples were analyzed by Western blot 
utilizing merlin and GST antibodies. 
The first and second lanes of Figure 17 exhibit the apparent molecular weights of 
the recombinant proteins His-mer-NT and His-mer-NT∆PBD1, respectively, and were 
used as references for this binding assay.  The results show that the N-terminus of merlin 
was detected in the GST-pax-LD3 lane, but that the merlin N-terminus minus the PBD1 
sequence was not.  These results confirm that, in vitro, paxillin LD3 binds directly to the 
merlin N-terminus, and that specifically, the binding occurs directly between the paxillin 
LD3 motif and the merlin PBD1 domain.  This conclusion is supported by the result 
which demonstrates that deletion of the merlin PBD1 sequence abrogates binding to the 
paxillin LD3 domain.  The results of these experiments are significant in that, to date, 
there are no published reports documenting the identification of binding partners for the 





























































Figure 17.  GST-Paxillin LD3 Binds Directly to His-Merlin N Term, but Not to His-
Merlin N Term Lacking the PBD1 Domain. 
GST-paxillin LD3 fusion proteins (0.25µg), immobilized on glutathione sepharose beads, 
were incubated with the His-merlin N term and His-merlin N term lacking the PBD1 
domain (0.25µg) fusion proteins.  The proteins were resolved by SDS-PAGE (12%), and 
Western blot analyses were performed using rabbit anti-merlin A19 and goat anti-GST 
antibodies.  His-mer-NT and His-mer-NT∆PBD1 were run to verify their molecular 
weights as detected by the merlin A19 antibody.  The upper band present in the GST-pax 
LD3 / His-mer-NT lane indicates that the merlin N-terminus binds directly to paxillin at 
LD domain 3, in vitro.  The lower band in this same lane verifies the presence of the 
GST-pax-LD3 fusion protein as detected by the GST antibody.  The absence of a band 
corresponding to the molecular weight of the His-mer-NT∆PBD1 in the GST-pax LD3 / 
His-mer-NT∆PBD1 lane indicates that the deletion of PBD1 abrogates merlin binding to 
paxillin. The band detected in this same lane verifies the presence of the GST-pax-LD3 in 
the assay.  As a negative control, the absence of a band corresponding to the molecular 
weight of the His-mer-NT in the GST-beads / His-mer-NT lane demonstrates that the 
recombinant His proteins do not bind to the GST tag non-specifically. 
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Merlin-β1 Integrin Interactions 
 
Schaller et al. has demonstrated that the membrane-proximal region of the β1 
integrin cytoplasmic domain associates with paxillin (Schaller et al., 1995), and merlin 
and β1 integrin have been shown to associate in SCs (Obremski et al., 1998; Taylor et al., 
2003).  Additionally, merlin and paxillin have been shown to bind in a direct manner 
(Fernandez-Valle et al., 2002).  Based on these observations, it is of significance to 
determine whether merlin directly binds to the cytoplasmic domain of β1 integrin. 
In the first experiment of this series, direct binding assays were conducted 
between the GST-β1 integrin cytoplasmic domain (cd) and both the His-merlin fusion 
proteins (mer1: merlin isoform 1, and mer2: merlin isoform 2) and the His-paxillin fusion 
protein.  All recombinant proteins were produced as described previously.  The GST-β1cd 
fusion proteins were immobilized onto Glutathione Sepharose beads, and the His-mer1, -
mer2, and -pax fusion proteins were added separately to the buffer of each of the GST-
β1cd samples.  Following incubation and rinsing, the samples were analyzed by Western 
blot using merlin, T7, and GST antibodies.  Figure 18A shows the results of the binding 
assays between the GST-β1cd and the His-merlin and His-paxillin fusion proteins, while 
Figure 18B demonstrates equal loading of the GST-β1cd fusion protein.  As seen in Figure 
18A, all three of the His-tagged fusion proteins exhibited binding to GST-β1cd.  The fact 
that binding was also exhibited in the negative control lanes (GST-beads and GST) as 
well, suggested that the binding and rinsing buffer compositions were not stringent 
enough to disallow non-specific binding.  This finding led to additional experiments 


































































































Figure 18.  GST-β1 Integrin Cytoplasmic Domain Binds Directly to His-Merlin 1, 
His-Merlin 2, and His-Paxillin. 
The GST-β1cd fusion protein (3.0ng), immobilized on glutathione sepharose beads, was 
incubated with His-merlin1, His-merlin2, and His-paxillin (1.0ng) fusion proteins.  The 
proteins were resolved by SDS-PAGE (8%), and Western blot analyses were performed 
using the rabbit anti-merlin A19 and T7 antibodies. The His-mer1, His-mer2, and His-
pax recombinant proteins were run alone to demonstrate their apparent molecular 
weights.  The results indicate that the His-mer1, His-mer2, and His-pax fusion proteins 
bound to GST-β1cd, as well as did all of the negative controls, suggesting a high degree 
of non-specific binding (A). Following the initial blotting, the membrane was stripped 
and re-probed with goat anti-GST to demonstrate equal loading of the GST-β1cd fusion 
protein (B).  
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for each set of proteins.  Optimal buffer conditions were unable to be determined (in the 
time given) for the binding assay between GST-β1cd and His-paxillin, therefore this line 
of research was set aside. 
Buffer stringencies were determined for the assay between the β1cd and merlin 
fusion proteins, and it was decided to limit the assay to merlin isoform 1, versus both 
isoforms 1 and 2.  Therefore, the next experiment focused on the binding interactions 
between GST-β1cd and the His-merlin N- (His-mer-NT) and C-termini (His-mer-CT) 
fusion proteins.  Recombinant proteins were produced as described previously.  GST-β1cd 
proteins were immobilized onto Glutathione Sepharose beads, and the His-mer-NT and 
His-mer-CT fusion proteins were added separately to each sample.  Following incubation 
and extensive rinsing, the samples were analyzed by Western blot using merlin and GST 
antibodies.  Figure 19A shows that the C terminus of merlin was detected in the GST-
β1cd lane.  This result indicates that direct binding occurs, in vitro, between the 
cytoplasmic domain of β1 integrin and the merlin C-terminus.  No merlin was detected in 
the beads / His-mer-CT control lane.  This result supports the validity of the binding 
shown between the merlin C-terminus and the cytoplasmic domain of β1 integrin 
indicating that this binding is not the result of non-specific interactions.  As the Western 
blot analyses show in Figure 19A, the merlin N-terminus was not detected in the GST-
β1cd / His-mer-NT lane.  This result appears to indicate that no binding occurred between 
the N-terminus of merlin and the cytoplasmic domain of β1 integrin.  But when the 




























































































































































































































































































Figure 19.  The GST-β1 Cytoplasmic Domain Binds Directly to the C-Terminus 
of Merlin. 
GST-β1cd fusion proteins (3.0ng), immobilized on glutathione sepharose beads, were 
incubated with the recombinant proteins His-mer-NT and His-mer-CT (1.0ng).  The 
proteins were resolved by SDS-PAGE (12%), and Western blot analyses were performed 
using rabbit anti-merlin A19 and C18 antibodies. The His-mer-NT and His-mer-CT 
fusion proteins were run alone to demonstrate their apparent molecular weights. The 
results indicate that the C-terminus of merlin binds to the cytoplasmic domain of β1 
integrin, in vitro (A). Following the initial blotting, the membrane was stripped and re-
probed with goat anti-GST for equal loading purposes (B). 
 64
of GST-β1cd within the binding assay, recombinant GST-β1cd was only weakly detected 
in the GST-β1cd / His-mer-NT lane (Figure 19B).  This data provides inconclusive 
evidence as to the interactions between these two fusion proteins, as there may not have 
been enough GST-β1cd present on the beads to facilitate binding between them and the 
His-mer-NT protein.  Additionally, as seen in Figure 19B, no GST was detected in the 
GST-beads / His-mer-NT control lane, as there should be.  These results suggest that 
perhaps a contaminant of some type was introduced into the purified batch of His-mer-
NT recombinant protein which caused the dissociation of the recombinant proteins from 
the beads.  Additional research should be conducted in order to determine whether or not 




Merlin, an ERM family protein, has been shown to dimerize with its ERM family 
member ezrin, both in vitro and in vivo (Grönholm et al., 1999).  This interaction, 
coupled with the demonstration of direct binding between merlin and paxillin, suggests 
that paxillin-ezrin interactions should be investigated.  Direct binding assays were 
conducted between the His-paxillin and the GST-ezrin fusion proteins.  Both the paxillin 
and ezrin recombinant proteins were produced as described previously.  The GST-ezrin 
fusion proteins were immobilized onto Glutathione Sepharose beads, and His-paxillin 
was added to each sample.  Because of previous difficulties in determining the optimal 
buffer conditions when using His-paxillin fusion proteins in a direct binding assay, this 
experiment was set up, in parallel, utilizing both low-salt (137mM) and high-salt 
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(500mM) buffer conditions.  Following incubation and extensive rinsing under both sets 
of buffer conditions, the samples were analyzed by Western blot using T7 and GST 
antibodies.  As seen in Figure 20A, under the low-salt conditions, paxillin was detected 
strongly in the GST-ez-NT lane.  Additionally, paxillin was detected, although much 
weaker, in the ezrin full-length and C-terminus lanes, as well as in the beads-alone 
control lane.  Because paxillin was also detected in the negative control lane (beads / His-
paxillin) the results of all binding detected under the low-salt conditions should be 
interpreted as non-specific.  Figure 20B displays the results of the parallel binding assay 
conducted utilizing high-salt buffers, and Figure 20C demonstrates equal loading of the 
GST-ezrin proteins.  Under high-salt buffer conditions, paxillin was detected in the GST-
ez-NT lane, indicating that, in vitro, paxillin binds directly to the N-terminus of ezrin.  In 
support of this result, no paxillin was detected in either of the negative control lanes 
(beads / His-paxillin and GST-beads / His-paxillin), indicating that the paxillin-ezrin 





























































































Figure 20.  His-Paxillin-FL Binds to the Ezrin-N-Terminus Under High Salt Buffer 
Conditions. 
GST-ezrin fusion proteins (0.5µg) were immobilized onto 20µl (bed volume) of 
Glutathione Sepharose beads, and His-paxillin(0.5µg) was added to each sample.  The 
samples were incubated and rinsed with 1X Tris-HCl containing 0.1% TX-100 with 
either 137mM or 500mM NaCl.  The proteins were resolved by SDS-PAGE (10%), and 
Western blot analyses were performed using mouse anti-T7 antibody.  The results 
indicate that under low salt buffer conditions, binding of GST-ez-FL, -NT, and CT occurs 
with His-paxillin. The binding between these proteins is non-specific as binding of His-
paxillin to the negative control (beads-alone) also occurs (A). Under high salt (500mM) 
buffer conditions, the results indicate that the N-terminus of ezrin binds to paxillin, in 
vitro (B).  Following initial blotting, the membrane was stripped and reprobed with goat 




 Although it is well established that merlin functions as a tumor suppressor, its 
biological mechanism of action as it functions as a tumor suppressor has yet to be 
completely determined.  The goal of this thesis was to examine the molecular 
relationships between merlin and a few of its various interactors within the signal 
transduction pathways of SCs.  The results of this investigation will serve to further 
illuminate merlin’s tumor suppressor function mechanism of action in SCs.  The major 
findings of this thesis research are as follows: 
 
1. The paxillin LD3 motif mediates merlin-paxillin interactions, in vitro, by binding 
directly to the merlin PBD1 domain, 
2. The cytoplasmic domain of β1 integrin binds directly to the merlin C-terminus, in 
vitro, and  





 As stated previously, research conducted in this laboratory has demonstrated that 
merlin interacts with paxillin in a direct manner through two separate and specific 
sequences within the merlin molecule termed PBD1 and PBD2, for paxillin binding 
domain 1 and 2, respectively (Fernandez-Valle et al., 2002).  For the purpose of 
determining which paxillin amino acid sequence(s) aids in facilitating the merlin-paxillin 
interactions, a series of binding assays was conducted.  The data obtained from the first 
of these experiments suggest that the N-terminus of paxillin is instrumental in mediating 
merlin-paxillin interactions.  Further experiments, which demonstrate that LD3 binds to 
the merlin N-terminus and that LD’s 2 and 3 bind to the merlin C-terminus, illustrate that 
multiple paxillin LD motifs play an important role in the binding of paxillin to both the 
N- and C-termini of merlin.  The results revealing that more than one paxillin LD motif 
binds to merlin is consistent with previous research.  FAK has been shown to bind to both 
the LD2 and LD4 domains of paxillin, while vinculin has been shown to bind the LD1, 
LD2, and LD4 motifs (Brown et al., 1996; Turner et al., 1999). 
 Paxillin LD3 is an integral factor in the binding between merlin and paxillin, as is 
suggested by the results which reveal that LD3 interacts with both the amino and carboxy 
termini of merlin.  Reinforcing this supposition, the final merlin-paxillin binding results 
presented here demonstrate that the paxillin LD3 motif interacts directly and specifically 
with the merlin PBD1 domain, in vitro.  From this result, it can be interpreted that both 
the paxillin LD3 and merlin PBD1 sequences are crucial for mediating merlin-paxillin 
binding.  This conclusion is supported by the result which demonstrates that deletion of 
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the merlin PBD1 sequence abrogates binding to the paxillin LD3 motif.  The finding that 
paxillin LD3 specifically mediates direct binding to merlin PBD1 fleshes out the model 
of merlin-paxillin interactions in SCs proposed by our laboratory (Fernandez-Valle et al., 
2002).  Briefly stated, it is specifically the LD3 domain of paxillin, through its binding to 
merlin at PBD1, which positions merlin at the plasma membrane where it can interact 
with various signaling proteins.  Figure 21 illustrates the direct interaction between 
merlin and paxillin. 
 The discovery of a binding partner to the paxillin LD3 motif is of some 
significance in and of itself as, to date, there are no published reports documenting the 
identification of binding partners for the paxillin LD3 motif (Brown & Turner, 2004). 
 
 
Merlin-β1 Integrin Interactions 
 
Studies show that merlin co-immunoprecipitates and co-localizes with β1 integrin 
in SCs (Obremski et al., 1998; Taylor et al., 2003).  More recently, research has revealed 
that merlin and paxillin bind each other directly (Fernandez-Valle et al., 2002).  
Additionally, our laboratory has shown that merlin is recruited into a β1 integrin complex 
at the plasma membrane.  The results of these studies raised the question of whether 
merlin binds directly to β1 integrin or associates with β1 integrin through paxillin.  To 
determine the answer to this question, direct binding assays were performed between 
merlin and the β1 integrin cytoplasmic domain.  The assay results indicate that the 





















Figure 21.  The 1st Direct Binding Partner for the Paxillin LD3 Domain Has Been 
Identified as the Merlin PBD1 Domain. 
The paxillin LD3 motif binds directly to the PBD1 domain of merlin, in vitro.  This 
conclusion is supported by results which demonstrate that the deletion of the merlin 
PBD1 sequence abrogates binding to the paxillin LD3 domain. 
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This conclusion is consistent with research which shows that talin, a FERM family 
protein like merlin, binds directly to β1A, a β1 integrin cytoplasmic domain splice variant 
(Pfaff et al., 1998).  Additional studies reveal that the C-terminal rod of talin can bind to 
the cytoplasmic domains of both β1 and β3 integrins (Martel et al., 2000; Xing et al., 
2001). 
Based on the results presented in this thesis, coupled with the current research 
sited, one could theorize that merlin, in it’s open and inactive conformation (in terms of 
tumor suppressor function), is shuttled to the plasma membrane by paxillin LD3 for the 
purpose of binding to the cytoplasmic domain of β1 integrin in order to transmit growth 
permissive signals.  Figure 22 illustrates the proposed binding interactions between 
merlin, paxillin, and β1 integrin. 
Interestingly, it had been proposed that there are two integrin binding sites per 
talin molecule (Knezevic et al., 1996).  This supposition has since been proven true.  In 
addition to its C-terminus binding to β integrins, studies have revealed that the N-
terminal FERM domain of talin is able to bind to the membrane-proximal region of β 
integrin cytoplasmic tails (Calderwood et al., 1999; Patil et al., 1999).  Because it has 
been shown that there are both N- and C-terminal integrin binding domains on talin, it 
has been suggested that the globular head and rod-like tail domains of talin participate in 
cooperative binding to integrins (Yan et al., 2001).  Based on this information, future 
studies should be conducted to determine whether the N-terminus of merlin also binds to 
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Figure 22.  Merlin/Paxillin/β1 Integrin Binding Model. 
Merlin, in its open and inactive conformation (in terms of its tumor suppressor function), 
is shuttled to the plasma membrane, via the paxillin LD3 motif binding to the PBD1 
domain, for the purpose of binding to the cytoplasmic domain of β1 integrin in order to 





 Merlin and ezrin, both ERM family members, have demonstrated the ability to 
undergo both homo- and heterodimerization, in vitro and in vivo (Grönholm et al., 1999).  
These data, taken into consideration with this laboratory’s previous findings showing that 
the merlin N-terminus binds directly with paxillin (Fernandez-Valle et al., 2002), 
suggested that the interactions between ezrin and paxillin be examined.  To determine 
possible ezrin-paxillin interactions, direct binding assays were conducted between these 
two proteins.  The results of these assays indicate that the N-terminus of ezrin binds 
directly to paxillin, in vitro.  This finding is not unanticipated because, as stated 
previously, the N-terminus of merlin has been shown to bind directly to paxillin 
(Fernandez-Valle et al., 2002).  Additionally, merlin and ezrin, as family members, 
exhibit 61% identity between their FERM domains (Turunen et al., 1998) and are 
therefore expected to share at least some binding partners.  Consistent with this 
supposition, research shows that merlin and ezrin do bind to several common proteins 
such as CD44 and RhoGDI (Sainio et al., 1997; Takahashi et al., 1997). 
 Although merlin and ezrin, as well as the other ERMs, have been shown to form 
head-to-tail associations, limited research is available hypothesizing the possible 
functions of these various heterodimers.  Competitive binding studies demonstrate that 
the C-ERMAD of merlin has a higher affinity for the N-ERMAD of ezrin than for its own 
N-terminus (Nguyen et al., 2001).  Research demonstrates that the N-terminus of ezrin 
binds directly to the cytoplasmic domain of CD44, an integral membrane protein (Hirao 
et al., 1996), and immunofluorescence microscopy has revealed that merlin colocalizes 
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with ezrin and CD44 beneath the cell membrane (Sainio et al., 1997).  Additionally, 
recent research indicates that merlin-ezrin heterodimerization is promoted by activated 
PKA phosphorylation of merlin at S518 (Alfthan et al., 2004). 
 
 
Proposed Model of Merlin/Paxillin/β1 Integrin/Ezrin Interactions 
 
 Based on the research cited, and coupled with the results presented in this thesis, 
it could be theorized that paxillin acts as a scaffold bringing ezrin and merlin into close 
proximity, through direct binding to both proteins, whereby the PKA-mediated 
phosphorylation of merlin at S518 promotes their heterodimerization.  In this scenario, 
paxillin also function as a shuttle transporting the merlin-ezrin complex, via its LD3 
motif binding to merlin PBD1, to the plasma membrane.  This then positions, by way of 
their head-to-tail association, the N-terminus of ezrin for binding to CD44 and the C-
terminus of merlin for binding to the β1 integrin cytoplasmic domain.  As depicted in 
Figure 23, the proposed interactions between merlin, paxillin, β1 integrin, and ezrin result 
in the formation of a signaling complex coordinating both Schwann cell proliferation and 
motility.  Additional in vivo research, such as immunofluorence staining and localization 








































Figure 23.  Model of Merlin/Paxillin/β1 Integrin/Ezrin Interactions in Proliferating 
and Quiescent Schwann Cells. 
Our laboratory has proposed that, in quiescent Schwann cells, paxillin binds to merlin 
through its C-terminal PBD2 domain and removes merlin from the membrane 
(Fernandez-Valle et al., 2002).  Adding to this model, the results presented in this thesis 
suggest that the N-terminus of ezrin also binds to paxillin, bringing merlin and ezrin into 
close proximity (right panel).  As cAMP levels increase, activated PKA phosphorylates 
merlin at S518 promoting the heterodimerization between merlin and ezrin.  The 
merlin/ezrin complex is then shuttled to the plasma membrane by paxillin, through 
binding of its LD3 motif to merlin’s PBD1 domain.  At the membrane, the C-terminus of 
the merlin then binds to β1 integrin and the N-terminus of ezrin binds to CD44, resulting 






Albelda, S. M. & Buck, C. A.  (1990).  Integrins and other cell adhesion molecules.  
Federation of American Societies for Experimental Biology, 4 (11), 2868-2880. 
 
Alfthan, K., Heiska, L., Grönholm, M., Renkema, H., & Carpén, O.  (2004).  Cyclic 
AMP-dependent protein kinase phosphorylates merlin at serine 518 independently 
of p21-activated kinase and promotes merlin-ezrin heterodimerization.  The 
Journal of Biological Chemistry, 279 (18), 18559-18566. 
 
Bach, I.  (2000).  The LIM domain: regulation by association.  Mechanisms of 
Development, 91, 5-17. 
 
Barret, C., Roy, C., Montcourrier, P., Mangeat, P., & Niggli, V.  (2000).  Mutagenesis of 
the phophatidylinositol 4,5-bisphosphate (PIP2) binding site in the NH2-terminal 
domain of ezrin correlates with its altered cellular distribution.  The Journal of 
Cell Biology, 151, 1067-1080. 
 
Bianchi, A. B., Hara, T., Ramesh, V., Gao, J., Klein-Szanto, A. J., Morin, F., Menon, A. 
G., Trofatter, J. A., Gusella, J. F., Seizinger, B. R., & Kley, N.  (1994).  Mutations 
in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour 
types.  Nature Genetics, 6 (2), 185-192. 
 
Brault, E., Gautreau, A., Lamarine, M., Callebaut, I., Thomas, G., & Goutebroze, L.  
(2001).  Normal membrane localization and actin association of the NF2 tumor 
suppressor protein are dependent on folding of its N-terminal domain.  Journal of 
Cell Science, 114, 1901-1912. 
 
Bretscher, A., Chambers, D., Nguyen, R., & Reczek, D.  (2000).  ERM-Merlin and 
EBP50 protein families in plasma membrane organization and function.  Annual 
Review of Cell and Developmental Biology, 16, 113-143. 
 
Bretscher, A., Edwards, K., & Fehon, R. G.  (2002).  ERM proteins and merlin: 
integrators at the cell cortex.  Nature Reviews: Molecular Cell Biology, 3, 586-
599. 
 
Brockes, J. P., Fields, K. L., & Raff, M. C.  (1979).  Studies on cultured rat Schwann 
cells. I. Establishment of purified populations from cultures of peripheral nerve.  
Brain Research, 165 (1), 105-118.
77 
Brockes, J. P., Breakefield, X. O., & Martuza, R. L.  (1986).  Glial growth factor-like 
activity in Schwann cell tumors.  Annals of Neurology, 20, 317-322. 
 
Brown, M. C., Perrotta, J. A., & Turner, C. E.  (1996).  Identification of LIM3 as the 
principal determinant of paxillin focal adhesion localization and characterization 
of a novel motif on paxillin directing vinculin and focal adhesion kinase binding.  
The Journal of Cell Biology, 135 (4), 1109-1123. 
 
Brown, M. C., Perrotta, J. A., & Turner, C. E.  (1998).  Serine and threonine 
phosphorylation of the paxillin LIM domains regulates paxillin focal adhesion 
localization and cell adhesion to fibronection.  Molecular Biology of the Cell, 9, 
1803-1816. 
 
Brown, M. C., Curtis, M. S., & Turner, C. E.  (1998).  Paxillin LD motifs may define a 
new family of protein recognition domains.  Nature Structural Biology, 5 (8), 
677-678. 
 
Brown, M. C. & Turner, C. E.  (2004).  Paxillin: adapting to change.  Physiological 
Reviews, 84, 1315-1339. 
 
Bunge, R. P. & Fernandez-Valle, C.  (1995).  Basic biology of the schwann cell.  In: 
Neuroglia.  Kettenmann, H., & Ranson, B., eds.  New York, 44-57. 
 
Burridge, K. & Chrzanowska-Wodnicka, M.  (1996).  Focal adhesions, contractility, and 
signaling.  Annual Review of Cell and Developmental Biology, 12, 463-519. 
 
Calderwood, D. A., Zent, R., Grant, R., Rees, D. J. G., Hynes, R. O., & Ginsberg, M. H.  
(1999).  The talin head domain binds to integrin β subunit cytoplasmic tails and 
regulates integrin activation.  The Journal of Biological Chemistry, 274 (40), 
28071-28074. 
 
Chen, L., Bailey, D., & Fernandez-Valle, C.  (2000).  Association of β1 integrin with 
focal adhesion kinase and paxillin in differentiating Schwann cells.  Journal of 
Neuroscience, 20 (10), 3776-3784. 
 
Chishti, A. H., Kim, A. C., Marfatia, S. M., Lutchman, M., Hanspal, M., Jindal, H., Liu, 
S.-C., Low, P. S., Rouleau, G. A., Mohandas, N., Chasis, J. A., Conboy, J. G., 
Gascard, P., Takakuwa, Y., Huang, S.-C., Benz, Jr, E. J., Bretscher, A., Fehon, R. 
G., Gusella, J. F., Ramesh, V., Solomon, F., Marchesi, V. T., Tsukita, Sh., 
Tsukita, Sa., Arpin, M., Louvard, D., Tonks, N. K., Anderson, J. M., Fanning, A. 
S., Bryant, P. J., Woods, D. F., & Hoover, K. B.  (1998).  The FERM domain: a 
unique module involved in the linkage of cytoplasmic proteins to the membrane.  
Trends in Biochemical Science, 23, 281-282. 
78 
Côté, J.-F., Turner, C. E., & Tremblay, M. L.  (1999).  Intact LIM3 and LIM4 domains of 
paxillin are required for the association to a novel polyproline region (Pro2) of 
protein-tyrosine phosphatase-PEST.  The Journal of Biological Chemistry, 274 
(29), 20550-20560. 
 
Deguen, B., Mérel, P., Goutebroze, L., Giovannini, M., Reggio, H., Arpin, M., & 
Thomas, G.  (1998).  Impaired interaction of naturally occurring mutant NF2 
protein with actin-based cytoskeleton and membrane.  Human Molecular 
Genetics, 7 (2), 217-226. 
 
den Bakker, M. A., Riegman, P. H. J., Suurmeijer, A. P., Vissers, C. J., Sainio, M., 
Carpén, O., & Zwarthoff, E. C.  (2000).  Evidence for a cytoskeleton attachment 
domain at the N-terminus of the NF2 protein.  Journal of Neuroscience Research, 
62, 764-771. 
 
Dumanski, J. P., Carlbom, E., Collins, V. P., & Nordenskjöld, M.  (1987).  Deletion 
mapping of a locus on human chromosome 22 involved in the oncogenesis of 
meningioma.  Proceedings of the National Academy of Sciences, USA, 84, 9275-
9279. 
 
Feltri, M. L., Porta, D. G., Prevatali, S. C., Modari, A., Migliavacca, B., Cassetti, A., 
Littlewood-Evans, A., Reichardt, L. F., Messing, A., Quattrini, A., Mueller, U., & 
Wrabetz, L.  (2002).  Conditional disruption of β1 integrin in Schwann cells 
impedes interaction with axons.  The Journal of Cell Biology, 156 (1), 199-209. 
 
Fernandez-Valle, C., Gwynn, L., Wood, P. M., Carbonetto, S., & Bunge, M.  (1994).  
Anti-β1 integrin antibody inhibits Schwann cell myelination.  Journal of 
Neurobiology, 25 (10), 1207-1226. 
 
Fernandez-Valle, C., Tang, Y., Ricard, J., Rodenas-Ruano, A., Taylor, A., Hackler, E., 
Biggerstaff, J., & Iacovelli, J.  (2002).  Paxillin binds schwannomin and regulates 
its density-dependent localization and effect on cell morphology.  Nature 
Genetics, 31 (4), 354-362. 
 
Frazer, K. A., Boehnke, M., Budarf, M. L., Wolff, R. K., Emanuel, B. S., Myers, R. M., 
& Cox, D. R.  (1992).  A radiation hybrid map of the region on human 
chromosome 22 containing the neurofibromatosis type 2 locus.  Genomics, 14 (3), 
574-584. 
 
Garratt, A. N., Voiculescu, O., Topilko, P., Charnay, P., & Birchmeier, C.  (2000).  A 
dual role of erbB2 in myelination and in expansion of the schwann cell precursor 
pool.  The Journal of Cell Biology, 148 (5), 1035-1046. 
 
Gary, R. & Bretscher, A.  (1995).  Ezrin self-association involves binding of an N-
terminal domain to a normally masked C-terminal domain that includes the F-
actin binding site.  Molecular Biology of the Cell, 6 (8), 1061-1075. 
 79
Gautreau, A., Louvard, D., & Arpin, M.  (2002).  ERM proteins and NF2 tumor 
suppressor: the yin and yang of cortical actin organization and cell growth 
signaling.  Current Opinion in Cell Biology, 14, 104-109. 
 
Gonzalez-Agosti, C., Xu, L., Pinney, D., Beauchamp, R., Hobbs, W., Gusella, J., & 
Ramesh, V.  (1996).  The merlin tumor suppressor localizes preferentially in 
membrane ruffles.  Oncogene, 13, 1239-1247. 
 
Gonzalez-Agosti, C., Wiederhold, T., Herndon, M. E., Gusella, J., & Ramesh, V.  (1999).  
Interdomain interaction of merlin isoforms and its influence on intermolecular 
binding to NHE-RF.  The Journal of Biological Chemistry, 274 (48), 34438-
34442. 
 
Grönholm, M., Sainio, M., Zhao, F., Heiska, L., Vahare, A., & Carpén, O.  (1999).  
Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor 
suppressor protein merlin and the ERM protein ezrin.  Journal of Cell Science, 
112, 895-904. 
 
Gusella, J. F., Ramesh, V., MacCollin, M., & Jacoby, L. B.  (1996).  Neurofibromatosis 
2: loss of merlin’s protective spell.  Current Opinion in Genetics & Development, 
6, 87-92. 
 
Gusella, J. F., Ramesh, V., MacCollin, M., & Jacoby, L. B.  (1999).  Merlin:  the 
neurofibromatosis 2 tumor suppressor.  Biochimica et Biophysica Acta, 1423, 
M29-M36. 
 
Gutamnn, D. H., Giordano, M. J., Fishbach, A. S., & Guha, A.  (1997).  Loss of merlin 
expression in sporadic meningiomas, ependymomas, and schwannomas.  
Neurology, 48, 267-270. 
 
Gutmann, D. H., Geist, R. T., Xu, H., Kim, J. S., & Saporito-Irwin, S.  (1998).  Defects in 
neurofibromatosis 2 protein function can arise at multiple levels.  Human 
Molecular Genetics, 7, 335-345. 
 
Gutmann, D. H., Haipek, C. A., & Lu, K. H.  (1999).  Neurofibromatosis 2 tumor 
suppressor protein, merlin, forms two functionally important intramolecular 
associations.  Journal of Neuroscience Research, 58, 706-716. 
 
Gutmann, D. H.  (2001).  The neurofibromatoses: when less is more.  Human Molecular 
Genetics, 10 (7), 747-755. 
 
Haack, H. & Hynes, R. O.  (2001).  Integrin receptors are required for cell survival and 
proliferation during development of the peripheral glial lineage.  Developmental 
Biology, 233, 38-55. 
 
 80
Herreros, L., Rodríguez-Fernández, J. L., Brown, M. C., Alonso-Lebrero, J. L., Cabañas, 
C., Sánchez-Madrid, F., Longo, N., Turner, C. E., & Sánchez-Mateos, P.  (2000).  
Paxillin localizes to the lymphocyte microtubule organizing center and associates 
with the microtubule cytoskeleton.  The Journal of Biological Chemistry, 275 
(34), 26436-26440. 
 
Hirao, M., Sato, N., Kondo, T., Yonemura, S., Monden, M., Sasaki, T., Takai, Y., 
Tsukita, Sh., & Tsukita, Sa.  (1996).  Regulation mechanism of ERM 
(ezrin/radixin/moesin) protein/plasma membrane association: possible 
involvement of phosphatidylinositol turnover and Rho-dependent signaling 
pathway.  The Journal of Cell Biology, 135 (1), 37-51. 
 
Hoellerer, M. K., Noble, M. E. M., Labesse, G., Campbell, I. D., Werner, J. M., & Arold, 
S. T.  (2003).  Molecular recognition of paxillin LD motifs by the focal adhesion 
targeting domain.  Structure, 11, 1207-1217. 
 
Hovens, C. M. & Kaye, A. H.  (2001).  The tumour suppressor protein NF2/merlin: the 
puzzle continues.  Journal of Clinical Neuroscience, 8 (1), 4-7. 
 
Hynes, R. O.  (2002).  Integrins:  bidirectional, allosteric signaling machines.  Cell, 110, 
673-687. 
 
Hynes, R. O.  (2003).  Changing partners.  Science, 300, 755-756. 
 
Jessen, K. R. & Mirsky, R.  (2002).  Signals that determine schwann cell identity.  
Journal of Anatomy, 200 (4), 367-376. 
 
Kissil, J. L., Johnson, K. C., Eckman, M. S., & Jacks, T.  (2002).  Merlin phosphorylation 
by p21-activated kinase 2 and effects of phosphorylation on merlin localization.  
The Journal of Biological Chemistry, 277 (12), 10394-10399. 
 
Kimura, Y., Saya, H., & Nakao, M.  (2000).  Calpain-dependent proteolysis of NF2 
protein: involvement in schwannomas and meningiomas.  Neuropathology, 20, 
153-160. 
 
Knezevic, I., Leisner, T. M., & Lam, S. C.-T.  (1996).  Direct binding of the platelet 
integrin αIIbβ3 (GPIIb-IIIa) to talin.  The Journal of Biological Chemistry, 271 
(27), 16416-16421. 
 
LaJeunesse, D. R., McCartney, B. M. & Fehon, R. G.  (1998).  Structural analysis of 
drosophila merlin reveals functional domains important for growth control and 
subcellular localization.  The Journal of Cell Biology, 141 (7), 1589-1599. 
 
 81
Lamorte, L., Rodrigues, S., Sangwan, V., Turner, C. E., & Park, M.  (2003).  Crk 
associates with a multimolecular paxillin/GIT2/beta-PIX complex and promotes 
Rac-dependent relocalization of paxillin to focal contacts.  Molecular Biology of 
the Cell, 14 (7), 2818-2831. 
 
Lee, J. W. & Juliano, R. L.  (2002).  The α5β1 integrin selectively enhances epidermal 
growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in 
intestinal epithelial cells.  Biochimica et Biophysica Acta, 1542, 23-31. 
 
Liddington, R. C.  (2002).  Will the real integrin please stand up?  Structure, 10, 605-607. 
 
Liu, S., Calderwood, D. A., & Ginsberg, M. H.  (2000).  Integrin cytoplasmic domain-
binding proteins.  Journal of Cell Science, 113, 3563-3571. 
 
Lutchman, M. & Rouleau, G. A.  (1996).  Neurofibromatosis type 2: a new mechanism of 
tumor suppression.  Trends in Neurosciences, 19 (9), 373-377. 
 
Martel, V., Vignoud, L., Dupé, S., Frachet, P., Block, M. R., & Albigès-Rizo, C.  (2000).  
Talin controls the exit of the integrin α5β1 from an early compartment of the 
secretory pathway.  Journal of Cell Science, 113, 1951-1961. 
 
Martin, T. A., Harrison, G., Mansel, R. E., & Jiang, W. G.  (2003).  The role of the 
CD44/ezrin complex in cancer metastasis.  Critical Reviews in 
Oncology/Hematology, 46, 165-186. 
 
Martuza, R. L & Eldridge, R.  (1988).  Neurofibromatosis 2.  The New England Journal 
of Medicine, 318 (11), 684-688. 
 
Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K., Tsukita, Sa., & 
Tsukita, Sh.  (1998).  Rho-kinase phosphorylates COOH-terminal threonines of 
ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association.  
The Journal of Cell Biology, 140 (3), 647-657. 
 
Matsui, T., Yonemura, S, Tsukita, S., & Tsukita, S.  (1999).  Activation of ERM proteins 
in vivo by Rho involves phosphatidyl-inositol 4-phosphate 5-kinase and not 
ROCK kinases.  Current Biology, 9, 1259-1262. 
 
Maurel, P. & Salzer, J. L.  (2000).  Axonal regulation of Schwann cell proliferation and 
survival and the initial events of myelination requires PI 3-kinase activity.  The 
Journal of Neuroscience, 20 (12), 4635-4645. 
 
Meyer, D. & Birchmeier, C.  (1995).  Multiple essential functions of neuregulin in 
development.  Nature, 378, 386-390. 
 
 82
Mirsky, R., Jessen, K. R., Brennan, A., Parkinson, D., Dong, Z., Meier, C., Parmantier, 
E., & Lawson, D.  (2002).  Schwann cells as regulators of nerve development.  
Journal of Physiology, 96, 17-24. 
 
Narod, S. A., Parry, D. M., Parboosingh, J., Lenoir, G. M., Ruttledge, M., Fischer, G., 
Eldridge, R., Martuza, R. L., Frontali, M., Haines, J. L., Gusella, J. F., & Rouleau, 
G. A.  (1992).  Neurofibromatosis type 2 appears to be a genetically homogeneous 
disease.  American Journal of Human Genetics, 51 (3), 486-496. 
 
Nguyen, R., Reczek, D., & Bretscher, A.  (2001).  Hierarchy of merlin and ezrin N- and 
C-terminal domain interactions in homo- and heterotypic associations and their 
relationship to binding of scaffolding proteins EBP50 and E3KARP.  The Journal 
of Biological Chemistry, 276 (10), 7621-7629. 
 
Nikolopoulos, S. N. & Turner, C. E.  (2000).  Actopaxin, a new focal adhesion protein 
that binds paxillin LD motifs and actin and regulates cell adhesion.  The Journal 
of Cell Biology, 151 (7), 1435-1447. 
 
Nikolopoulos, S. N. & Turner, C. E.  (2001).  Integrin-linked kinase (ILK) binding to 
paxillin LD1 motif regulates ILK localization to focal adhesions.  The Journal of 
Biological Chemistry, 276 (26), 23499-23505. 
 
Obremski, V. J., Hall, A. M., & Fernandez-Valle, C.  (1998).  Merlin , the 
neurofibromatosis type 2 gene product, and β1 integrin associate in isolated and 
differentiating Schwann cells.  Journal of Neurobiology, 37, 487-501. 
 
Patil, S., Jedsadayanmata, A., Wencel-Drake, J. D., Wang, W., Knezevic, I., & Lam, S. 
C.-T.  (1999).  Identification of a talin-binding site in the integrin β3 subunit 
distinct from the NPLY regulatory motif of post-ligand binding functions.  The 
Journal of Biological Chemistry, 274 (40), 28575-28583. 
 
Pearson, M. A., Reczek, D., Bretscher, A., & Karplus, P. A.  (2000).  Structure of the 
ERM protein moesin reveals the FERM domain fold masked by an extended actin 
binding tail domain.  Cell, 101, 259-270. 
 
Previtali, S., Feltri, M. L., Archelos, J. J., Quattrini, A., Wrabetz, L., & Hartung, H.-P.  
(2001).  Role of integrins in the peripheral nervous system.  Progress in 
Neurobiology, 64, 35-49. 
 
Pfaff, M., Liu, S., Erle, D. J., & Ginsberg, M. H.  (1998).  Integrin β cytoplasmic domains 
differentially bind to cytoskeletal proteins.  The Journal of Biological Chemistry, 
273 (11), 6104-6109. 
 
Pykett, M. J., Murphy, M., Harnish, P. R., & George, D. L.  (1994).  The 
neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternatively 
spliced transcripts.  Human Molecular Genetics, 3 (4), 559-564. 
 83
Rong, R., Surace, E. I., Haipek, C. A., Gutmann, D. H., & Ye, K.  (2004).  Serin 518 
phosphorylation modulates merlin intramolecular association and binding to 
critical effectors important for NF2 growth suppression.  Oncogene, 23 (52), 
8447-8454. 
 
Rouleau, G. A., Wertelecki, W., Haines, J. L., Hobbs, W. J., Trofatter, J. A., Seizinger, B. 
R., Martuza, R. L., Superneau, D. W., Conneally, P. M., & Gusella, J. F.  (1987).  
Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on 
chromosome 22.  Nature, 329, 246-248. 
 
Rouleau, G. A., Seizinger, B. R., Wertelecki, W., Haines, J. L., Superneau, D. W., 
Martuza, R. L., & Gusella, J. F.  (1990).  Flanking markers bracket the 
neurofibromatosis type 2 (NF2) gene on chromosome 22.  American Journal of 
Human Genetics, 46, 323-328. 
 
Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-
Xaun, K., Demczuk, S., Desmaze, C., Plougastel, B., Pulst, S. M., Lenoir, G., 
Bijlsma, E., Fashold, R., Dumanski, J., de Jong, P., Parry, D., Eldridge, R., 
Aurias, A., Delattre, O., & Thomas, G.  (1993).  Alteration in a new gene 
encoding a putative membrane-organizing protein causes neuro-fibromatosis type 
2.  Nature, 363, 515-521. 
 
Ruggieri, M. & Huson, S. M.  (1999).  The neurofibromatoses. An overview.  Italian 
Journal of Neurological Science, 20, 89-108. 
 
Sainio, M., Zhao, F., Heiska, L., Turunen, O., den Bakker, M., Zwarthoff, E., Lutchman, 
M., Rouleau, G. A., Jääskeläinen, J., Vaheri, A., & Carpén, O.  (1997).  
Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 
and associates with actin-containing cytoskeleton.  Journal of Cell Science, 110, 
2249-2260. 
 
Sainio, M., Jääskeläinen, J., Pihlaja, H. & Carpén, O.  (2000).  Mild familial 
neurofibromatosis 2 associates with expression of merlin with altered COOH-
terminus.  Neurology, 54, 1132-1138. 
 
Sastry, S. K. & Burridge, K.  (2000).  Focal adhesions: a nexus for intracellular signaling 
and cytoskeletal dynamics.  Experimental Cell Research, 261, 25-36. 
 
Schaller, M. D., Otey, C. A., Hildebrand, J. D., & Parsons, J. T.  (1995).  Focal adhesion 
kinase and paxillin bind to peptides mimicking β integrin cytoplasmic domains.  
The Journal of Cell Biology, 130 (5), 1181-1187. 
 
Schaller, M. D.  (2001).  Paxillin: a focal adhesion-associated adaptor protein.  
Oncogene, 20, 6459-6472. 
 
 84
Scherer, S. S.  (2002).  Myelination: some receptors required.  The Journal of Cell 
Biology, 156 (1), 13-15. 
 
Schlaepfer, D. D., Hauck, C. R., & Sieg, D., J.  (1999).  Signaling through focal adhesion 
kinase.  Progress in Biophysics & Molecular Biology, 71, 435-478. 
 
Schuppan, D., Somasundaram, R., Dieterich, W., Ehnis, T., & Bauer, M.  (1994).  The 
extracellular matrix in cellular proliferation and differentiation  Annals New York 
Academy of Sciences, 733, 87-102. 
 
Scoles, D. R., Chen, M., & Pulst, S.-M.  (2002).  Effects of Nf2 missense mutations on 
schwannomin interactions.  Biochemical and Biophysical Research 
Communications, 290, 366-374. 
 
Seizinger, B. R., Martuza, R. L., & Gusella, J. F.  (1986).  Loss of genes on chromosome 
22 in tumorigenesis of human acoustic neuroma.  Nature, 322 (6080), 644-647. 
 
Seizinger, B. R., De La Monte, S., Atkins, L., Gusella, J. F., & Martuza, R. L.  (1987a).  
Molecular genetic approach to human meningioma: Loss of genes on 
chromosome 22.  Proceedings of the National Academy of Sciences, USA, 84, 
5419-5423. 
 
Seizinger, B. R., Rouleau, G., Ozelius, L. J., Lane, A. H., St. George-Hyslop, P., Huson, 
S., Gusella, J. F., & Martuza, R. L.  (1987b).  Common pathogenetic mechanism 
for three tumor types in bilateral acoustic neurofibromatosis.  Science, 236 
(4799), 317-319. 
 
Shaw, R. J., McClatchey, A. I., & Jacks, T.  (1998b).  Regulation of the 
neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and 
growth arrest stimuli. The Journal of Biological Chemistry, 273 (13), 7757-7764. 
 
Shaw, R. J., Paez, J. G., Curto, M., Yaktine, A., Pruitt, W. M., Saotome, I., O’Bryan, J. 
P., Gupta, V., Ratner, N., Der, C. J., Jacks, T., & McClatchey, A.I.  (2001).  The 
NF2 tumor suppressor, merlin, functions in rac-dependent signaling.  
Developmental Cell, 1, 63-72. 
 
Shen, Y., Schneider, G., Cloutier, J.-F., Veillette, A., & Schaller, M. D.  (1998).  Direct 
association of protein-tyrosine phosphatase PTP-PEST with paxillin.  The Journal 
of Biological Chemistry, 273 (11), 6474-6481. 
 
Sherman, L., Xu, H., Geist, R. T., Saporito-Irwin, S., Howells, N., Ponta, H., Herrlich, P., 
& Gutmann, D. H.  (1997).  Interdomain binding mediates tumor growth 
suppression by the NF2 gene product.  Oncogene, 15, 2505-2509. 
 
 85
Shimizu, T., Seto, A., Maita, N., Hamada, K., Tsukita, Sh., Tsukita, Sa., & Hakoshima, 
T.  (2002).  Structural basis for neurofibromatosis type 2.  The Journal of 
Biological Chemistry, 277 (12), 10332-10336. 
 
Simons, P. C., Pietromonaco, S. F., Reczek, D., Bretscher, A., & Elias, L.  (1998).  C-
terminal threonine phosphorylation activates ERM proteins to link the cell’s 
cortical lipid bilayer to the cytoskeleton.  Biochemical and Biophysical Research 
Communications, 253, 561-565. 
 
Smith, W. J., Nassar, N., Bretscher, A., Cerione, R. A., & Karplus, P. A.  (2003).  
Structure of the active N-terminal domain of ezrin.  The Journal of Biological 
Chemistry, 278 (7), 4949-4956. 
 
Sun, C., Robb, V. A., & Gutmann, D. H.  (2002).  Protein 4.1 tumor suppressors: getting 
a FERM grip on growth regulation.  Journal of Cell Science, 115, 3991-4000. 
 
Takahashi, K., Sasaki, T., Mammoto, A., Takaishi, K., Kameyama, T., Tsukita, Sa., 
Tsukita, Sh., & Takai, Y.  (1997).  Direct interaction of the Rho GDP dissociation 
inhibitor with ezrin/radixin/moesin initiates the activation of the small Rho G 
protein.  The Journal of Biological Chemistry, 272 (37), 23371-23375. 
 
Taylor, A. R., Geden, S. E., & Fernandez-Valle, C.  (2003).  Formation of a β1 integrin 
signaling complex in Schwann cells is independent of Rho.  GLIA, 41, 94-104. 
 
Trofatter, J. A., MacCollin, M. M., Rutter, J. L., Murrell, J. R., Duyao, M. P., Parry, D. 
M., Eldridge, R., Kley, N., Menon, A. G., Pulaski, K., Haase, V. H., Ambrose, C. 
M., Munroe, D., Bove, C., Haines, J. L., Martuza, R. L., MacDonald, M. E., 
Seizinger, B. R., Short, M. P., Buckler, A. J., & Gusella, J. F.  (1993).  A novel 
moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor 
supressor.  Cell, 72, 791-800. 
 
Tsukita, S. & Yonemura, S.  (1999).  Cortical actin organization: lessons from ERM 
(Ezrin/Radixin/Moesin) proteins.  The Journal of Biological Chemistry, 274 (49), 
34507-34510. 
 
Tumbarello, D. A., Brown, M. C., & Turner, C. E.  (2002).  The paxillin LD motifs.  
Federation of European Biochemical Societies Letters, 513, 114-118. 
 
Turner, C. E. & Miller, J. T.  (1994).  Primary sequence of paxillin contains putative SH2 
and SH3 domain binding motifs and multiple LIM domains: identification of a 
vinculin and pp125FAK-binding region.  Journal of Cell Science, 107, 1583-1591. 
 86
Turner, C. E, Brown, M. C., Perrotta, J. A., Riedy, M. C., Nikolopoulos, S. N., 
McDonald, A. R., Bagrodia, S., Thomas, S., & Leventhal, P. S.  (1999).  Paxillin 
LD4 motif binds PAK and PIX through a novel 95-kD ankyrin repeat, ARF-GAP 
protein: a role in cytoskeletal remodeling.  The Journal of Cell Biology, 145 (4), 
851-863. 
 
Turner, C. E.  (2000).  Paxillin and focal adhesion signaling.  Nature Cell Biology, 2 (12), 
E231-E236. 
 
Turner, C. E.  (2000).  Paxillin interactions.  Journal of Cell Science, 13 (Pt23), 4139-
4140. 
 
Turunen, O., Sainio, M., Jääskeläinen, J., Carpén, O., & Vaheri, A.  (1998).  Structure-
function relationships in the ezrin family and the effect of tumor-associated point 
mutations in neurofibromatosis 2 protein.  Biochimica et Biophysica Acta, 1387, 
1-16. 
 
Wagner, A. L.  (2003).  Neurofibromatosis Type 2.  Retrieved June 1, 2005, from 
http://www.emedicine.com/radio/topic475.htm. 
 
Wertelecki, W., Rouleau, G. A., Superneau, D. W., Forehand L. W., Williams, J. P., 
Haines, J. L., & Gusella, J. F.  (1988).  Neurofibromatosis 2: clinical and DNA 
linkage studies of a large kindred.  New England Journal of Medicine, 319 (5), 
278-283. 
 
Wolff, R. K., Frazer, K. A., Jackler, R. K., Lanser, M. J., Pitts, L. H., & Cox, D. R.  
(1992).  Analysis of chromosome 22 deletions in neurofibromatosis type 2-related 
tumors.  American Journal of Human Genetics, 51 (3), 478-485. 
 
Woodrow, M. A., Woods, D., Cherwinski, H. M., Stokoe, D., & McMahon, M.  (2003).  
Ras-induced serine phosphorylation of the focal adhesion protein paxillin is 
mediated by the Raf→MEK→ERK pathway.  Experimental Cell Research, 287, 
325-338. 
 
Xiao, G., Chernoff, J., & Testa, J. R.  (2003).  NF2: The wizardry of merlin.  Genes, 
Chromosomes & Cancer, 38, 389-399. 
 
Xing, B., Jedsadayanmata, A., & Lam, S. C.-T.  (2001).  Localization of an integrin 
binding site to the C terminus of talin.  The Journal of Biological Chemistry, 276 
(48), 44373-44378. 
 
Xu, H. & Gutmann, D. H.  (1998).  Merlin differentially associates with the microtubule 
and actin cytoskeleton.  Journal of Neuroscience Research, 51, 403-415. 
 
 87
Yan, B., Calderwood, D. A., Yaspan, B., & Ginsberg, M. H.  (2001).  Calpain cleavage 
promotes talin binding to the β3 integrin cytoplasmic domain.  The Journal of 
Biological Chemistry, 276 (30), 28164-28170. 
 
Zanazzi, G., Einheber, S., Westreich, R., Hannocks, M., Bedell-Hogan, D., Marchionni, 
M. A., & Salzer, J. L.  (2001).  Glial growth factor/neuregulin inhibits Schwann 
cell myelination and induces demyelination.  The Journal of Cell Biology, 152 
(6), 1289-1299. 
 88
